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Psoriatic arthritis is an inflammatory arthritis affecting a fifth of patients 
with skin psoriasis.  Inflammation of the joints and tendons causes pain, 
stiffness, reduced function and disability.  Work disability is increasingly 
recognised as an important, patient centred, functional measure of disease 
yet little is known about work disability in psoriatic arthritis.  The overall 
aim of my thesis is to examine patient reported work disability in 
psoriatic arthritis by undertaking the following; 
 A systematic review of the relevant literature 
 Classification of a cohort of patients to study 
 Validation of a commonly used work outcome measure used in 
other rheumatic diseases 
 Selection of a suitable measure of structural damage to inflamed 
joints for investigating the associations of work disability in 
longitudinal observational studies.  
The results of the systematic review identified limited data reporting high 
levels of work disability associated with a wide variety of disease and 
non-disease related factors.  The review also identified the lack of a 
validated outcome measure for use in psoriatic arthritis.  I report the 
classification of a large single centre longitudinal cohort of patients with 
psoriatic arthritis and evidence supporting the retrospective application of 
a psoriatic arthritis classification criterion.  Subsequently I report a 
preliminary validation study of the work productivity and activity 
impairment questionnaire to measure work disability in psoriatic arthritis 
and a further study comparing the existing measures of structural damage 
in psoriatic arthritis.  Finally I developed and supervised a multicentre 
observational study to examine the associations of work disability in 
psoriatic arthritis.  The study identified reduced work effectiveness to be 
associated with measures of disease activity, whereas unemployment was 
associated with recent disease onset, greater age and worse physical 
function.  The study will provide a valuable cohort for prospective study 
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of work disability and the effect of medical treatment and will form part 




AIMS AND OBJECTIVES 
 
Aims 
The aims of this thesis are to systematically and critically review the 
current body of knowledge of work disability in psoriatic arthritis, 
validate a tool for measuring work disability in psoriatic arthritis, 
estimate the burden of work disability using this validated tool and 
investigate the associations with disease activity, structural damage, 
demographic and social factors. 
 
Objectives 
1. To systematically review the current body of knowledge of work 
disability in psoriatic arthritis. 
2. To classify an existing cohort of patients with psoriatic arthritis 
according to the classification criteria for psoriatic arthritis 
(CASPAR) criteria modified for retrospective application. 
3. To examine the feasibility, construct and discriminative validity 
of the work productivity and activity specific health questionnaire 
in psoriatic arthritis. 
4. To examine the association between structural damage and work 
disability through: 
a. Identification of the optimal radiographic tool for use in 
longitudinal observational studies in psoriatic arthritis 
through assessment of the feasibility and sensitivity to 
change in structural joint damage of the four existing 
radiographic assessment tools.  
b. To determine to what extent structural damage is 
associated with work disability measured with the work 
productivity and activity specific health questionnaire 
using the method selected under (4a). 
5. To determine to what extent clinical disease activity, 
demographic and social factors are associated with work 
disability measured with the work productivity and activity 











The aim of my thesis is to examine patient reported Work Disability 
(WD) in Psoriatic Arthritis (PsA).  This will be achieved through a 
systematic review of the current body of knowledge, identification and 
classification of an appropriate cohort of patients to study, preliminary 
validation of a tool to measure WD, assessment of the optimal measure to 
use for assessment of criterion validity and a cross sectional study to 
examine the associations of PsA with WD.  Here I will set out the 
reasons for why measuring disease outcome in PsA is important.  
 
PsA is an inflammatory arthritis occurring in 7-42% of patients with 
psoriasis.1  Inflammation of joints and tendons leads to pain, stiffness, 
reduced movement and subsequent disability.  Originally considered a 
benign disease it is now recognised that PsA can be serious and 
progressive with significant physical, psychological, functional and 
social impairment. 2-5  There is increasing awareness that WD is an 
important patient centred, quality of life measure of outcome in 
rheumatic disease.  WD has a detrimental impact on an individual’s 
financial status and quality of life.6  Whilst there is a large body of 
information on the burden of WD in related rheumatic diseases such as 
rheumatoid arthritis and ankylosing spondylitis 7 to date there is little 
data on WD in PsA.8, 9  PsA will now be introduced in more detail to 
explain why separate investigation of WD in this disease is warranted.  
 
Psoriatic arthritis 
Psoriasis is an inflammatory skin condition affecting 2-3% of the UK 
population.10  The exact prevalence of PsA is unknown.  Current 
estimates suggest 14%  of patients with psoriasis in UK general practice11 
and 20-35% of patients with psoriasis in dermatology clinics have PsA.12  
In a recent review the mean age of onset of PsA was between 40.7 and 





Psoriatic arthritis has a heterogeneous but distinct clinical phenotype.  A 
number of features help to distinguish PsA from the most common 
inflammatory arthritis, rheumatoid arthritis. PsA affects men and women 
equally whereas rheumatoid arthritis is more common in women.11, 13-15  
In rheumatoid arthritis peripheral joints are affected in a strikingly 
symmetrical pattern across rows of joints on both sides.  Conversely PsA 
has a tendency to affect joints along a ‘ray’ such that the 
metacarpophalangeal (MCP), proximal interphalangeal (PIP) and distal 
interphalangeal (DIP) joints may be affected along one digit.16  
rheumatoid arthritis may affect the synovial atlanto-axial joint (joining 
the 1st and 2nd cervical vertebrae) but PsA tends to cause inflammation at 
other sites in the spine (spondyloarthritis).  In 1973 Moll and Wright 
described five patterns of PsA; symmetrical polyarthritis (15%), 
asymmetrical oligoarthritis (70%), predominant distal interphalangeal 
joint disease (5%), predominantly spondyloarthritits (5%) and arthritis 
mutilans (5%).16  There is evidence that even these patterns are not fixed 
and that they may evolve over the course of disease.  A longitudinal 
study of 87 patients with PsA observed that 18 patients changed between 
phenotypes over a mean follow up of 65 months.3  
 
Enthesitis (inflammation of the tendon insertion to bone) and 
tenosynovitis (inflammation of the tendon and tendon sheath) are further 
characteristic clinical manifestations of PsA distinguishing it from 
rheumatoid arthritis.  PsA may cause tendon and joint inflammation, 
together leading to diffuse swelling of an entire digit, termed dactylitis or 
sausage digit.17, 18  Ultrasound studies of lower limb entheses have 
demonstrated that enthesitis is more common than is clinically evident 
and more common in those with psoriasis than in healthy individuals.19, 20  
Inflammation of these sites will lead to a distinct pattern of symptoms 




PsA appears after, or synchronously with, the onset of psoriasis in the 
majority of patients.14, 21  In a minority (18 – 13%) the arthritis precedes 
the onset of psoriasis.14, 21  Nail pitting (sharply defined depressions in 
the nail plate) and onycholysis (separation of the nail from the bed) is 
indistinguishable from that seen in psoriasis.22  However nail lesions are 
more common in patients with PsA than those with psoriasis alone23 and 
in those with DIP joint disease.22 
 
PsA has a characteristic radiographic appearance.  Erosions (areas of 
discrete interruption of the bone surface) and joint space narrowing are 
seen in most types of inflammatory arthritis.  In PsA there are additional 
changes, which include the presence of bony proliferation (bone growth), 
periostitis (inflammation of the bone surface), osteolysis (dissolution of 
bone) and ankylosis (bone fusion across a joint).2, 14, 24, 25  In one 
observational study of a secondary care cohort in the United States two 
thirds of patients with PsA had radiographic damage at the first visit to a 
PsA specialist .14  A longitudinal study of 139 patients with established 
PsA demonstrated the progressive nature of the disease.  Fifty-eight% of 
patients had radiographic damage at baseline (median 5 years disease 
duration) progressing to 78% at follow up (median 12 years disease 
duration).26 
 
In summary PsA is a disease with a varied phenotype, distinct from other 
forms of inflammatory arthritis, which will have a unique impact upon an 
individual’s physical, psychological and social functioning.  Separate 
investigation of the impact of this disease is therefore warranted.  A more 
detailed introduction of WD follows in order to explain why this is an 
important measure of disease outcome.  
 
Work disability in rheumatic disease 
There has been increasing interest in measuring work disability in 
rheumatic disease in recent years.  This stems from its importance to the 
individual in terms of financial and emotional wellbeing as well as the 
wider socio-economic perspective.  With the advent and rapid uptake of 
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highly effective but expensive drug treatments such as anti-Tumour 
Necrosis Factor (anti-TNF) inhibitors there is a need to provide an 
economic case for the cost-effectiveness of treatments through health 
economics analysis.  Traditionally this has been through cost of drugs, 
cost of hospital care and the quality adjusted life years (QALY) system.  
There is now a growing body of opinion that work disability in terms of 
productivity should be considered for inclusion in the National Institute 
of Clinical Excellence (NICE) cost-effectiveness models. 27  
 
Examination of what is known about WD in related conditions can 
inform studies in PsA.  Rheumatoid arthritis predominantly affects the 
hands and feet causing the same symptoms of pain, stiffness and reduced 
joint movement.  Studies in rheumatoid arthritis have demonstrated that 
between 20-40% of patients develop WD (absenteeism, sick leave or ill 
health retirement) in the first 2-3 years of disease onset and that this may 
be permanent.28-31  In a long term follow up study of early rheumatoid 
arthritis WD was seen to rise to 80% after 20 years disease duration.32  
ankylosing spondylitis is another related inflammatory arthritis, this time 
predominantly affecting the spine with symptoms of pain, stiffness and 
reduced movement.  Understanding WD in ankylosing spondylitis is 
relevant because PsA may also affect the spine in a similar pattern.  In an 
early systematic review of WD in ankylosing spondylitis WD ranged 
between 3 to 50% after 18 and 45 years of age respectively.33  A Swedish 
case control study of 122 patients with ankylosing spondylitis over a 
seven year period reported increased sickness benefit collection, sickness 
compensation and sick leave amongst those with ankylosing spondylitis 
compared with age and sex matched controls.34  A Norwegian cross 
sectional study of 360 patients with ankylosing spondylitis (mean disease 
duration 22.6 years) reported 43.6% were collecting WD benefit.35  A 
large cross sectional study of 699 patients with ankylosing spondylitis 
from the National Spanish Registry investigated prevalence of WD 
(disability benefit collection) and factors related to it.  The mean age of 
the ankylosing spondylitis population studied was 48.7 years and mean 
disease duration was 14.1 years.  Twenty six per cent were collecting a 
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work disability pension and this was associated with older age, male sex, 
longer disease duration, fatigue and radiographic damage.36  
 
WD in rheumatoid arthritis and ankylosing spondylitis is therefore high 
and occurs early in the disease course.  There has therefore been interest 
in the effect of treatment on WD, in particular studies comparing 
different classes of drug treatment. Comparison of biological and Disease 
Modifying Anti-Rheumatic Drugs (DMARD) in rheumatoid arthritis 
have demonstrated reduced absenteeism, reduced sick leave, higher 
employment potential and greater levels of employment potential 
amongst those treated with biologics.37  In a study comparing 
employment levels amongst patients commenced on DMARD 
(Methotrexate) versus Biologic (Etanercept) reported a close association 
between clinical improvement and remission and cessation of work.37  
Patients showing a greater response (70% versus 20%) were 72% less 
likely to stop working and 55% less likely miss work.37  Data from 139 
patients with ankylosing spondylitis in the south Swedish arthritis 
treatment group register reported higher baseline sick leave than the 
general population (25% versus 8%) and a decline in sick leave in the 
first 12 months anti-TNF therapy (25% to 12%).38  
 
There is therefore a burden of WD in rheumatic diseases.  There is also a 
need to measure WD, as it is only through accurate measurement that we 
may assess the burden of disability and effect of treatment interventions.  
The question therefore is how WD is best measured in patients with PsA?  
It is not possible to assume that measures of WD valid in ankylosing 
spondylitis or rheumatoid arthritis will perform in the same way in PsA.  
The many distinguishing features of PsA, not least the presence of skin, 
entheseal, axial disease and markedly different articular, radiographic 
and demographic features of PsA may result in unique effects on 
physical, psychological and social functioning. The following section is a 
discussion of the measurement of WD.  
 
Measurement of work disability 
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WD may be measured in a variety of ways and there is currently no 
consensus on the optimal method.  Do we measure unemployment, ill 
health retirement or job loss?  Absolute changes in employment are likely 
to have the greatest impact on an individual but occur infrequently, over 
periods of years and are therefore unlikely to be detected in short clinical 
trials or even registries.39  Do we measure absenteeism which may be 
more frequent and therefore detectible and if so do we assess short 
periods such as hours or longer periods such as days or weeks?  Other 
possibilities include patient reported employability, work instability or 
work satisfaction.  A concept gaining increasing interest is presenteeism; 
reduced effectiveness while at work as a measure of productivity loss 
(either taken alone or in combination with absenteeism).  At work, 
reduced effectiveness or shorter periods of absenteeism (such as hours, 
days, weeks) are likely to occur over a shorter time frame and are 
therefore a better measure if the ultimate goal is to assess response to 
treatment.  Absenteeism and presenteeism may precede events such as 
job loss, long term sick leave or retirement due to ill health, are more 
likely to be reversible, and as such they are more attractive targets for 
measurement.  Finally absenteeism and presenteeism are considered to be 
the  most relevant WD outcomes when considering health economics 
research.40 
 
PsA is therefore a unique disease with several clinical features distinct 
from rheumatoid arthritis and ankylosing spondylitis.  These 
distinguishing features may result in differing biological, psychological 
and social impacts of disease, therefore separate examination of WD in 
PsA is warranted.  In order to establish what is known about WD in PsA 










WORK DISABILITY IN PSORIATIC ARTHRITIS; 
A SYSTEMATIC REVIEW 
 
The first objective of this thesis is to systematically review the current 
body of knowledge of work disability in psoriatic arthritis.  The review 
was undertaken at the beginning of my study and has subsequently been 
published.41  The main body of the current chapter has been taken from 
that review and therefore may include some material already discussed in 




Work disability is an important functional outcome measure in arthritis.  
There is a large body of information on WD in rheumatic diseases such 
as rheumatoid arthritis and ankylosing spondylitis, however until now 
factors that influence work disability in psoriatic arthritis has not been 
systematically reviewed.  My objective was to perform a systematic and 
critical review of the current literature on work disability and its 
measurement in psoriatic arthritis. 
 
Methods 
A systematic literature search was conducted using Medline, Embase and 
Cochrane databases.  The search strategy was supplemented by a manual 
search of cited articles.  All original English language publications in the 
form of meta-analyses, randomised controlled trials (RCTs), 
observational studies and publications in abstract form were included.  A 
quality assessment was made of the articles published in full form.  
 
Results 
Nineteen publications (nine in abstract form) were identified.  There is 
intermediate quality evidence that levels of unemployment (20-50%) and 
WD (16-39%) are high and associated with longer disease duration, 
27 
 
worse physical function, high joint count, low educational level, female 
gender, erosive disease and manual work.  There is sparse low quality 
evidence that WD is worse in those with PsA than psoriasis alone.  
 
Conclusions 
Disability at work in those with PsA is high however data on its 
associations is limited by the small number of reports and heterogeneity 
of data collected.  Future work should focus on the validation of work 
disability data collection tools for use in PsA. 
 
INTRODUCTION 
Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in 7-42% 
of patients with psoriasis.1  Originally considered a benign disease it is 
now recognised that PsA can be serious and progressive.  Prospective 
studies have demonstrated progression of clinical joint scores and 
deteriorating functional status with increased disease duration.2-4  Patients 
with PsA also suffer with psoriasis that may itself cause significant 
physical, psychological, social and functional impairment. 5 
 
Disability in the workplace inevitably has a significant impact on an 
individual’s quality of life, financial status as well as society as a whole.6  
There is increasing awareness that work disability in the form of 
absenteeism (time away from work) and presenteeism (reduced 
effectiveness at work) are important patient centred, quality of life 
outcome measure in arthritis. Outcome Measures in Rheumatology 
(OMERACT) have included participation in the core set of outcome 
measures in PsA.42  Whilst there is a large body of information on the 
burden of WD and the validity of measurement tools in related rheumatic 
diseases such as rheumatoid arthritis and ankylosing spondylitis 7 to date 
there is little data on WD in PsA.8, 9  Assessment and validation of 
outcome measures of work disability in PsA warrants separate 
examination given the features that make PsA a unique disease such 
associated psoriasis, heterogeneity of disease phenotype and 




There are a number of observational cohort and controlled PsA studies 
that have measured aspects of work disability though the current body of 
evidence on WD in PsA has not yet been synthesised.  This review 
describes a systematic and critical review of the current literature on the 




A search was performed on the 2nd December 2010 in Medline (1950 to 
present), Embase (1988-present) and Cochrane databases using the 
following MeSH indexing and Keyword terms respectively; ‘arthritis, 
psoriatic’, ‘psoriatic arthritis’, ‘work’, ‘employment’, ‘absenteeism’ and 
‘presenteeism’.  The search strategy was supplemented by a manual 
reference search of cited articles.  All original English language 
publications in the form of meta-analyses, randomised controlled trials 
(RCT’s) and observational studies were included.  Following review of 
the abstracts all original articles which contained data on WD in PsA 
were included for final review.  Review articles, those not specific to PsA 
or not related to work disability were excluded.  A literature evaluation 
form was used to standardise data collection. Publications in abstract 
form are included however they have not been subject to the same peer 
review process as fully published articles.  In order to accommodate this 
and avoid placing undue weight to this data the abstracts have not been 
subject to the quality assessment and are described separately both in the 
results section and tables.  
 
Quality assessment 
Due to the differing methodologies employed meta-analysis was not 
possible.  Given the limited amount of published information on WD in 
PsA we deemed it unfeasible to exclude articles with methodological 
weakness without significantly limiting the information available.  
Therefore we have performed a quality assessment based on the presence 
of seven quality criteria; use of diagnostic criteria for PsA, analysis made 
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only on those of working age, response rate >80% or loss to follow up 
<30%, WD defined as due to PsA, use of external WD assessment, 
avoidance of recall bias and avoidance of confounding.  Confounding 
was considered to be avoided if data was collected and analysed on >3 
contextual factors that may influence WD including but not limited to; 
type of work, assistance at work, education, earnings, depression, co 
morbidities.  This results in an aggregate score out of seven.  Study 
quality was stratified in to three levels; Low <3, Intermediate 3-4, Good 
≥5.  The criteria used in this study are based on previously published 




The search identified 260 titles of which 94 were duplicates.  Of 166 
unique results 145 were excluded at abstract review as not specific to 
PsA, not related to work disability and review articles.  Twenty one 
original articles were included for full text analysis and two further 
articles were excluded using the same criteria.45, 46  Thus nineteen studies 
were included for final review.  Ten studies published in full form and 
nine in conference abstract form, no Cochrane reviews or meta-analyses 







21 Articles were 
retrieved for full 
text review 




Work  862,786 results 
Employment 97,090 results 
Absenteeism 15,157 results 
Presenteeism  14,909 results 
94 Articles  
excluded because they 
were duplicates 
145 Articles  
excluded because they 
were not related to 
PsA and WD or were 
review articles 
2 Articles excluded 
because there was no 
PsA specific data to 
report 
260 Articles  
were retrieved for 
abstract review 
19 Articles  
(9 in abstract form) 
were included for 
systematic review 
Figure 1  
 
Search tree for the systematic literature search of work disability in 
psoriatic arthritis 
 
The ten articles published in full form included 8,585 patients with PsA 
(Table 1). Study quality and work disability associations are summarised 
in table 2.  There was considerable variability in the work outcome 
measures used.  Furthermore authors occasionally labelled the same work 
outcome differently.  The term work disability may be the label given to 
‘disability benefit collection’ 9 or alternatively ‘not working due to ill 
health’ 39 or even a self-explanatory term not clarified in the 
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methodology.47 In this review we have made the exact measure used in 
each study explicit (Table 1). 
 
Seven studies reported rates of unemployment ranging 20 -50%. 39, 47-52  
Only two cohort studies specifically reported on unemployed caused by 
PsA rather than all causes, these studies reported unemployment levels of 
22% 52 and 23%.49  Seven studies measured absenteeism (working 
individuals not currently at work).39, 47, 48, 50-53  Two studies measured 
presenteeism. 48, 50  Two studies used external objective measures of WD 
(disability benefit/ ill health benefit collection).9, 49 
 
The study quality assessment is summarised in table 3.  Of the ten fully 
published articles only one study reached good quality status50, two 
studies were of intermediate quality 9, 52 and seven of low quality. 39, 47-49, 
51, 53, 54  Work disability was the primary outcome measure in only four 
studies. 9, 39, 49, 54  
 
Age  
One cohort study 39 investigated the  relationship between age and WD 
and found no association.  
 
Disease duration 
Three studies9, 39, 54 have reported on the association between WD and 
disease duration.  A cross-sectional Norwegian database study identified 
longer disease duration independently predicated WD as defined by 
disability benefit collection.9  In a German study of patients with 
rheumatic disease a reduced standardised employment ratio (SER) was 
demonstrated with increased disease duration irrespective of gender or 
geographical location (SER falling from 0.94 at 5 yrs to 0.70 at 10yrs in 
Men).54  However no such association was seen in the (British society of 
rheumatologists biologics registry) study of WD.39  There are no studies 
investigating WD in early PsA.  
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Table 1: Study design, demographics and work disability level estimated in the 10 papers published in full form 









Work Measure Work disability 
Christophers et al  48 CS 53 N/A Multinational 49 N/A Employment disadvantages 
questionnaire (EDQ) 
59% PsA pts unemployed 
 32% PsA work disabled 
 11% Psoriasis work disabled 
Gottlieb et al 47 CS 1122 N/A USA 48 7.2 Disability and employment 0.4% temporarily disabled, 4% disabled,  
8% unemployed 
Kaarela et al 49 PC 13 7.6yrs Finland 37 N/A Disability pension collection: 
Ill health retirement  
Absenteeism  
 
69% of PsA  pts were at wok compared with: 
 36% RA 
 85-90%AS. 
Kavanaugh et al 50 RCT 200 14wks USA 47 5.9 Sick days 
Productivity VAS  
Employability  
Employment 
16-19% Work disabled and 27-33% Unemployed;  
 
Productivity improved by: 
  67% in treatment arm vs  
 9% in placebo. 
 
Mau et al 54 CS 6041 N/A Germany 45 N/A Standardised Employment 
Ratio (SER) 
 
PsA had reduced employment (SER 0.92)  
 PsA (0.94) vs 
 RA, SLE, WG and SSc (0.76- 0.81). 
Radtke et al51 CS 338 N/A Germany 53 N/A Employment, absenteeism,  50% PsA patients working vs 60% those with PsO.  
 25% of working PsA patients had taken time off work vs 
 12% those with Psoriasis  
 
Roberts et al 53 PC 168 1-10yrs UK N/A N/A Employment, absenteeism, >1yr of work time was lost  
 62% of those with ‘deforming arthritis’ vs 
 3% with DIPJ and RA like  
Verstappen et al 39 PC 254 3yrs UK 45 14 Patient reported disability  
  
39%  Work disabled  
Wallenius et al 9 CS 271 N/A Norway 36 6 Disability benefit collection 33% women & 17% men work disabled 
Zhu et al 52 RC 125 1yr Hong Kong 48 6.9 Employment  59% of those with peripheral disease were employed vs  
39% of those with axial disease. 
RCT (R),  Prospective Cohort (PC), Retrospective Cohort (RC), Cross sectional Cohort (CS), Case series/ report (C), Not available (N/A), Rheumatoid arthritis 
(RA), Ankylosing Spondylitis (AS), Systemic Sclerosis (SSc), Wegeners Granulomatosis (WG), Systemic Lupus Erythematosis SLE).  
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Table 2; Work associations reported and study quality assessment  
 
1. If the information was not available or collected but not analysed a negative answer has been assumed  
2. Confounding is considered to be avoided if >3 contextual factors that may influence WD have been corrected for including; Work type, Assistance at work, Education, Earnings, Co morbidities, Depression, 
* Although data on confounders was not collected w assume randomisation has been effective mitigating confounding  





































































Christophers et al 
48 
 
- - - - - - - - - - - + - - - 1 
Gottlieb et al 47 
 
- - - - - - - - + - - - - + - 2 
Kaarela et al 49 
 
- - - - - - - - - - - - + + - 2 
Kavanaugh et al 50 
 
- - - - - - - - + - + + - + +* 5 
Mau et al 54 
 
- - - - - - + - - +^ - - - + - 2 
Radtke et al 51 
 
- - - - - - - - - - - - - - - 0 
Roberts et al 53 
 
+ - - - - - - - + - - - - - - 1 
Verstappen et al 39 
 
- + + - + - - + -$ + - - - - + 2 
Wallenius et al 9 
 
- - + + + + + - - - - - + + + 3 
Zhu et al 52 
 
+ - - - - - - - + + - + - - - 3 
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Table 3; Study design, demographics and quality principal findings of the 9 papers published in abstract form 
 
 
RCT (R),  Prospective Cohort (PC), Retrospective Cohort (RC), Cross sectional Cohort (CS), Case series/ report (C), Work Limitations Questionnaire (WLQ), Health and 
Labour Questionnaire (HLQ), Work Productivity Activity Index (WPAI), Willingness to Pay (WTP)
Source Study design Number Pts WD data 
collected 
Follow up Result 
Brodszky et  al 55 CS  
Cost of illness in PsA 




N/A 49% Work disabled 
Gladman et al  56 
Sampalis at al 57 
RCT  
ACCALAIM Sub analyses 
 
127 WLQ 12 weeks 23% Unemployed 
WLQ was reliable and correlated well with patient global activity  
Gladman et al  58  PC 
Study of Etanerecpt in PsA 
 
110 HLQ 2yrs Reduction in frequency of absenteeism after 2 years treatment 
 Baseline 0.8+/-2.5 days  
 Month 24 0.2+/-1.5 days 
 
Gladman et al 59 
 
RCT  
ACCALAIM  Sub analyses  
  
127 WLQ 12 weeks Improvement of WLQ after 12 wks of Adalimumab therapy  






1yr Improvement in productivity, employability and reduced absenteeism at wk 24,  
Kumar et al 61 CS 
Willingness to Pay study  
72  Employment N/A WTP was highest for intimacy, physical comfort, social comfort, emotional health 
and ability to sleep (median $1000 each). 
 
WTP was lowest for work or volunteering (median $300). 
Strober at al 62 RCT  
CHAMPION and REVEAL  





WPAI N/A The presence of any co morbidity in those with PsO (including PsA) had impaired 
quality of life and worse work productivity.  
Tang et al 63 CS 
Study from the 2008 National 
Health and Wellness survey 
413 WPAI N/A 63,000 respondents 413 (0.66%) had PsA: 
 




Joint count and radiographic damage 
One study reported a positive association between a high DAS 28 joint count and 
WD.39  One study reported higher levels of WD in those with axial vs peripheral 
PsA (39% vs 59%) 52 and another higher rates in ‘deforming PsA’ 62% vs distal 
interphalangeal joint and rheumatoid arthritis like patterns 3%.53  One cross 
sectional study reported an independent association between those with WD and 
erosive disease.9  
 
Physical function and quality of life 
Two studies investigated the association between WD and physical function 
(health assessment questionnaire).9, 39  Both studies reported a positive association 
independent of other measured parameters.  One further study 48 reported a 
positive association between the EQ5D (European Quality of life 5 Dimensions) 
health utility questionnaire and WD independent of age and gender.  It should be 
noted that such a correlation would be expected as contained within the EQ5D is a 
question referring to problems with ‘usual activities including work’. 
 
Psoriasis 
Two cross sectional studies compared WD in patients with PsA as compared with 
psoriasis alone48, 51, both reported increased work problems in those with PsA.  A 
large cross sectional study of 2009 patients with psoriasis included data on 338 
PsA patients.51  Fifty per cent of those with PsA were working vs sixty per cent of 
those with psoriasis.51  Of those working significantly more patients in the PsA 
group had taken time off work during the preceding year (25% vs 12%).  The 
questionnaire for this study did specify being unfit for work/ periods of absence 
from work specifically due to psoriasis rather than PsA which may have biased 
the results.  The second study also reported more work problems in the PsA group 
32% vs. Psoriasis alone 11%, p=0.0005.48  No studies have investigated the 
relative contribution of skin disease and joint disease to WD in patients with PsA 
however one randomised controlled trial assessing the effect of Infliximab in PsA 
did demonstrate less WD in those who achieved both 20% improvement in the 
American College of Rheumatology response criteria (ACR 20) and 75% 
improvement in the Psoriasis Area and Severity Index (PASI 75) rather than one 






One RCT 50 and one observational study 39 have investigated the effects of anti-
TNF treatment on WD.  Analysis from the IMPACT RCT study investigating the 
efficacy and safety of Infliximab in PsA reported on working status, sick days, 
productivity visual analogue scale (VAS) and patient reported employability (out 
of work but could work).50  Productivity improved between baseline and 14 weeks 
by 67% in treatment arm vs 9% in placebo (median VAS improvement 2.6 vs 
0.3).   The British society of rheumatologists biologics registry measured WD in 
patients with PsA, rheumatoid arthritis and ankylosing spondylitis over the first 
three years of biologic therapy.39  Baseline disability of the 229 patients with PsA 
was 39%.  The study did not demonstrate significant change in work status over 
three years.  Nine working patients became work disabled (6.9%) and 6 work 
disabled patients started working (6.1%).  
 
Environmental factors  
There is very limited data on the role of environmental factors such as type of 
work, support at work, job satisfaction, or labour market fluctuation on WD.  The 
study by Mau et al reported large differences in the standardised employment 
ratio (SER) across the economic divide of the old and new federal states in 
Germany.54  British society of rheumatologists biologics registry data 
demonstrated an increased rate of becoming WD in those with manual vs non-
manual jobs.39  
 
Personal factors 
Limited information is available on the association of WD and sex, marital status, 
education and earnings in PsA patients.  Two large cohort studies have reported 
female sex to be independently associated with WD.9, 39  Two cohort studies have 
reported low educational level to be independently associated with WD 9, 54 and 
one with greater cost of illness. 52  The IMPACT study noted no difference in WD 
between sex after 14 weeks treatment. 50 
 
Comparison with other rheumatic diseases 
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Two prospective cohort studies 39, 49 and one cross sectional study 54 have  
compared WD in PsA with other rheumatic diseases.  One long term follow up 
study reported 69% of PsA patients were at work compared with 36% rheumatoid 
arthritis, and 85-90% ankylosing spondylitis.49  This study contained only 13 
patients with PsA.  The British society of rheumatologists biologics registry 
registry reported high levels of WD in PsA of 39% compared with 41% 
ankylosing spondylitis, 49% rheumatoid arthritis.39  Mau et al used the 
standardised employment ratio to compare WD in those with PsA, rheumatoid 
arthritis, ankylosing spondylitis, Wegener's granulomatosis, systemic lupus 
erythematosus and systemic sclerosis.  Those with PsA had reduced employment 
(SER 0.92) at a level equivalent to AS (0.94) but better than rheumatoid arthritis, 
Wegener's granulomatosis, systemic lupus erythematosus and systemic sclerosis 
(0.76- 0.81).54 
  
Fatigue, Depression, comorbidities 
No studies have investigated the potential relationship between WD and fatigue, 
depression and comorbidities.  
 
Data published in abstract form 
Nine studies relating to WD in PsA were published in abstract form. The primary 
findings are summarised in table 3.  They confirm high rates of unemployment 
and disability reported in the fully published studies.  Interestingly these high 
rates are present irrespective of study design; biologic randomised controlled trials 
56, 57, 59, 62, 64, cohort studies 55, 58, 61 or population studies.63  Two aspects are 
noteworthy from this abstract data. Firstly the emerging use of standardised WD 
questionnaires. The abstracts include data collected with the following 
instruments; the Work Productivity Activity Index (WPAI) 62, 63, 65, Work 
Limitations Questionnaire (WLQ) 56, 57, Employment Disadvantages 
Questionnaire (EQD) 48 and Health and Labour Questionnaire (HLQ). 58  Only 
one of these studies undertook a validation exercise and these data have been 
published in two abstracts 56, 57 (table 3).  The work limitations questionnaire was 
found to demonstrate reliability and sensitivity to change.  There was a significant 
linear relationship between the work limitations questionnaire and Patient Global 
Assessment (PGA).  For every 6.5% improvement in patient global assessment 
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there was a 10% improvement in work labour questionnaire (P<0.001).  The 
second finding of interest is the possibility that medical treatment can mitigate 
work disability.  The GOlimumab Randomised EValuation of saftey and Efficacy 
in subjects with psoriatic Arthritis using a human anti-TNF monocLonal antibody 
(GOREVEAL) RCT reported improvement in productivity at week 24 and 
additional improvements in lost time from work and employability at week 52.60  
The study examining the safety and efficacy study of adalimumab in PsA- A 
Canadian open label study to evaluate the saftery and effeCtiveness of 
adaLimumab when Added to Inadequate therapy for the treatMent of psoriatic 
arthritis (ACCLAIM) RCT demonstrated an improvement in presenteeism 
independent of age, sex or disease duration at 12 weeks.56, 57, 59  Finally a study of 
Etanercept showed reduced absenteeism after two years; baseline: 0.8 days (+/-2.5 
days) within the prior 2 weeks falling to 0.2 days (+/-1.5 days) at month 24. 58 
  
DISCUSSION 
Employment is highly contextualised with multiple potential contributory factors 
that may influence an individual’s level of function or indeed readiness to reduce 
their working hours.  Such factors may include age and proximity to retirement, 
desire to work, support and flexibility of the employer, family and financial 
circumstances, education, ability to be flexible in role at work, the extent and 
access to benefits as well as the current local economic climate.  It is on this 
background that we attempt to measure work disability in patients with psoriatic 
arthritis.  
 
Work disability was the primary outcome measure in only four studies. 9, 39, 49, 54  
The study by Wallenius et al is a large cross sectional study measuring disability 
benefit collection.  This is an important study that has identified a number of WD 
associations (table 2).  The study weaknesses should be noted including; that 
disability pension measure was not specific to PsA, clinical diagnosis rather than 
diagnostic criteria for PsA were used for entry into the database and the age range 
included was not full working age (18-45) raising the potential for selection bias.  
The study by Verstappen et al investigates WD during the first three years of anti-
TNF therapy.  WD was high (39%) and did not change over the 3 years of 
treatment.  This negative result may in part be related to the timing of the baseline 
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data.  Recruitment was determined as ‘within 6/12’ of starting therapy therefore 
although the study was prospective in design there is a potential here of missing 
the point of maximal disability prior to biologics and  introducing recall bias 
despite the prospective study design.  The 1987 study by Kaarela et al is a Finnish 
cross sectional study of inflammatory arthritis.49  69% of PsA patients were at 
work compared with 36% rheumatoid arthritis, and 85-90% ankylosing 
spondylitis.  This study is limited by the very small numbers (13 patients with 
PsA) and calendar bias. Finally the elegant study by Mau et al measuring  
employment status on 6041 PsA patients was compared with rheumatoid arthritis, 
ankylosing spondylitis, Wegeners granulomatosis, systemic lupus erythematosus 
and systemic sclerosis using a standardised employment ratio (SER).54  A 
standardised employment ratio of one would mean no difference from the regional 
average.  Those with PsA had reduced employment at a level equivalent to but 
better than rheumatoid arthritis, systemic lupus erythematosus, Wegeners 
granulomatosis and systemic sclerosis.  The study uses an objective measure but 
is weakened by the lack of objective diagnostic criteria at entry and the limited 
scope of WD information collected. 
 
It is apparent that the broad spectrum and variable use of terminology is hindering 
our understanding of WD in PsA.  The majority of the studies report on ‘work 
disability’ though this may be the umbrella term for; benefit collection, percentage 
unemployed, frequency of absenteeism, self-reported disability, employability or 
the index values of a composite score.  The most frequently reported measures of 
WD are employment status (in work or not), absenteeism and to a lesser extent 
productivity/ presenteeism and disability benefit or retirement collection.  A 
common theme of the more recent studies has been the inclusion of a 
presenteeism measure.  Only two of the trials published in full form assessed 
presenteeism 48, 50 though six of the RCTs published in abstract form included this 
measure.56-58, 60, 62, 63  Presenteeism is an appealing concept as it is arguably the 
most feasible and responsive patient reported centred WD measure. Conceptual 
models of work disability have the common thread of considering work disability 
as a continuum from presenteeism leading through to short term absenteeism, long 
term absenteeism and finally job loss.7 Outcomes earlier in this continuum 
(presenteeism and short term absenteeism) are more likely to occur more 
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frequently and are more likely to be reversible than long term absenteeism or 
unemployment. As a result measures of employment and long term absenteeism 
are likely to be less responsive than presenteeism. 
 
When interpreting the individual disease and socioeconomic associations with 
WD some specific study limitations are worthy of discussion.  First, it is not 
possible to draw any conclusions on the association of WD with age as this has 
only been investigated in one study that was not specifically powered to detect 
such an association.52  Studies investigating WD in rheumatoid arthritis have 
taken differing approaches when assessing the association age with WD, either 
analysing all included or only those of working age.43  It may be most appropriate 
to assess unemployment only amongst those of working age but extend 
assessment of absenteeism, presenteeism and productivity loss to those of any age 
who are in work to give a truest reflection of the impact of disease on work.  
Second, the association with disease duration has been reported by three studies 
investigating disability benefit collection9, unemployment39, 54 and self-reported 
disability39 and though conflicting the findings are suggestive of an association of 
longer disease duration with worse disability.  Disease duration is likely to have 
differing effects on each form of WD.  It may be postulated that absenteeism and 
presenteeism will be greatest in early disease but after work and personal 
adaptations/ accommodations are made this impact will recede.  In established 
disease unemployment may be higher (if adaptations have not worked) leaving 
only those who are able to remain in work, who in turn may have less 
presenteeism.  Furthermore no study has investigated WD in early disease, a time 
known to be important in rheumatoid arthritis.43  The question of the influence of 
disease duration on WD is best answered through the prospective study of an 
inception cohort.  
 
The reports relating to joint disease activity and radiographic damage with WD 
indicate higher joint counts and erosive disease may be associated with higher 
levels of WD.  Caution should be made when interpreting these findings because 
these studies have employed the 28 joint counts employed in rheumatoid arthritis 
(rather than the full PsA 66/ 68 joint count) and the presence or absence of erosive 
disease, rather than a validated quantitative radiographic scoring method.  There is 
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more consistent evidence for the association of WD with physical function, 
reported in two studies, both specifically investigating WD as the primary 
outcome.9, 39 however both studies scored low on the quality assessment, 
specifically neither applied the CASPAR criteria or defined WD as related to PsA.  
 
When we consider the use of questionnaires to measure WD a large number are 
available 66 though none are validated for use in PsA.  Of the WD measures used 
in PsA only WLQ has been subject to any form of validation exercise published in 
abstract form.57, 59  This problem is not isolated to PsA.  Despite high quality 
validation exercises for WD data collection in other diseases such as the WPAI in 
ankylosing spondylitis 67 there is still work required to identify a fully validated 
questionnaire.  Recent data comparing estimates of presenteeism reported poor 
correlation between the following four measures; WLQ, HLQ, HPQ and WPAI.68  
Although there a number of measures available and there was consensus at the 
OMERACT 9 meeting that work disability is an important measure 66 no single 
tool has yet been endorsed. 
 
The quality assessment process has identified a theme of common weaknesses in 
the WD data included in these studies.  The purpose of our quality assessment was 
to assist the interpretation of the WD data within studies not to assess the overall 
quality of the study itself.  Table 2 emphasises that despite the apparently 
moderate number of publications there are common themes that weaken the 
results.  Lack of classification criteria for PsA, failure to apply analysis to the 
working age population and failure to account for potential confounding factors 
are the most frequent study deficits.  It should be highlighted that our quality 
assessment has some weaknesses. Firstly confounding is not avoided by simply 
accounting for 3 or more contextual factors though we felt it important that 
studies collect data and analysed for potential confounders given the large number 
of bio, psycho social influences on WD.  Secondly we have assumed that defining 
WD as ‘due to PsA’ is positive, though due to the complex interplay between PsA 
and its associated comorbidities restricting the outcome in this way may 
underestimate the burden of disability.  Finally the divisions of quality level 
though necessary for reporting are arbitrary.  The use of quality scores has been 
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debated 69 however the technique allows analysis of a topic where sparse 
information is available.  
 
ADDENDUM: Updated literature search 30/05/2013 
A repeat literature search was conducted on the 30/05/2013 identifying five 
further reports since the search made in December 2010.  Three have been fully 
published and two in abstract form.  
 
A report in abstract form by Gladman et al 58 is now available for more detailed 
evaluation following publication in full form.70  The Ratings and Evaluation in 
Psoriatic Arthritis with Embrel (REPArE) trial is a Canadian multicentre single 
arm observational study examining the long term effectiveness of Etanercept in 
the ‘real world’ setting of clinical practice.  The primary outcome is physical 
function measured with the health assessment questionnaire but included WD as a 
secondary outcome measured with the health and labour questionnaire. The health 
labour questionnaire reports in four modules, absence from work, reduced 
productivity at paid work, unpaid labour production and impediments to paid and 
unpaid labour.  The current report is of 24 month data.  The mean age was 48.4 
years, mean disease duration 8.1 years.  Fifty six per cent of patients reported >0.5 
improvement in health assessment questionnaire after 24 months treatment with 
Etanercept and 14% were free of disability.  There was no significant change in 
absenteeism or hours unpaid work.  There was a significant decline in mean 
number of hours of unpaid help that patients reported using in order to take care 
of home activities such as shopping, household work, childcare, odd jobs (8.0 vs 
4.8 hours, 95% CI -6.2 to -0.2 p=0.034).  Patient reported impediments to work 
fell significantly between baseline and follow up 1.5 (sd1.7 p<0.001).  Number of 
hours of paid and unpaid help decreased exponentially with improvement in 
health assessment questionnaire (p<0.001) and Fatigue Severity Scale (p<0.001).  
The mean tender and swollen joint counts improved as impediments to work fell 
(p<0.001).  The quality score (as applied in the systematic review)41 for this WD 
data was three out of seven, limited by the failure to apply a classification criteria, 
account for confounding factors, describe WD as related to PsA or use external 
criterion for WD.  In summary this randomised controlled trial adds to the body of 
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knowledge on the positive effect of treatment on work disability and the 
correlation of work disability with joint count, fatigue and physical function.  
 
Kavanaugh et al report a placebo controlled randomised controlled trial of the 
anti-TNF agent Golimumab.71  This report is a post-hoc analysis from the RCT 
examining the effect of Golimumab on HRQoL and productivity measured with a 
visual analogue score 0-10 at weeks 16, 24, 52 and 104.  An improvement in 
productivity was identified at week 24 (2.24± 2.89 p=0.0001).  The improvement 
appeared to be maintained out to week 104 however this did not reach 
significance (2.89±2.99, p=>0.05).  The change in productivity was moderately 
correlated with the clinical outcome of Disease Activity Score- 28 joint count 
(DAS28).  This study was a post hoc analysis therefore was not powered to detect 
change in productivity and achieved a quality score of two, perhaps explaining the 
loss of statistical significance at weeks 52 and 104.  The use of a visual analogue 
score to measure productivity loss is not validated in PsA but has been used in 
other trials and use of the visual analogue score is well validated in other 
outcomes such as pain and global activity as reviewed by Mease.50, 72  A final 
consideration when interpreting the findings of the study is the highly selected 
nature of randomised controlled trial participants, reducing the generalizability of 
the findings.  Nonetheless this study adds to the body of evidence that disease 
activity is associated with productivity loss and may be ameliorated with 
treatment.  
 
Kristensen at al report a retrospective case control analysis from 191 patients 
treated with anti-TNF between 2003 and 2009 from the South Swedish Arthritis 
Treatment Group Register.  Work disability information from the Swedish Social 
Insurance Agency was collected at 30-day intervals from 12 months before the 
start of treatment until 3 years after and compared to 764 age and sex matched 
controls.73  At the start of treatment 67% of the participants were work disabled.  
WD amongst participants remaining on treatment during the study fell from 12.5 
to 10.0 days per month.  Logistic regression identified prior work disability, anti-
TNF treatment failure, higher age, female sex and longer disease duration as being 
independently associated with WD.  This study achieved a high quality score of 
six and adds to the evidence for independent associations of WD, as listed, and the 
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effect of treatment however the findings need to be interpreted with caution.  
First, confounding by indication should be considered as those commencing anti-
TNF will be intrinsically different from others with PsA, likely more severe 
disease and thus may inflate the associations with clinical activity.  Second, the 
analysis was per-protocol rather than intention to treat and thus will have over-
estimated the ‘real world’ efficacy of treatment, participants are followed over the 
initial phase of treatment and some of the improvement seen may have been 
regression to the mean.  Third, the regression analysis did not include many 
potentially important factors such as education, work type and comorbidities.  
Finally Sweden has a particularly supportive social security system for those with 
ill health and thus this study may reflect higher rates of WD than in other 
countries.  The WD data from this study is of high quality and provides further 
evidence of the burden of WD in PsA.  
 
Noppakun et al reported data from an Etanercept randomised controlled trial in 
abstract form.74  This study compared etanercept 50mg bi-weekly with 50mg once 
weekly.  The aim of the current report was to compare quality of life (EQ5D) and 
work disability (WPAI) in subjects with PsA vs psoriasis alone.  240 subjects 
were included for analysis, 84 had PsA.  At baseline those with PsA had worse 
quality of life than psoriasis alone (EQ5D 0.55 vs 0.70 p<0.001) and work 
impairment (35.8% vs 24.8% p =0.022).  At week 24 quality of life and work 
impairment improved in both groups (0.79 vs 0.85) and work impairment (14% in 
both groups).  The numbers in the study are small and the proportion of 
participants employed is not reported but taken together will adversely affect the 
study power.  Carter et al reported on data from the US WPAI ‘re-contact study’ 
in abstract form.75  Participants were recruited from an internet panel.  Inclusion 
criteria were; age over 18, employed currently or in the last two years and having 
self-identified as having physician diagnosed atrial fibrillation, neck or lower back 
pain, PsA, psoriasis or stroke. 498 participants had psoriasis and 347 PsA.  Those 
with PsA patients had higher WPAI scores in all domains than atrial fibrillation or 
stroke.  Psoriasis patients reported more presenteeism than atrial fibrillation or 
stroke. PsA and psoriasis costs for absenteeism over the preceding seven days 
were $5748 and $2350 and overall work impairment costs $17413 vs $11790.  No 
statistical comparison was reported between PsA and psoriasis alone.  Due to the 
45 
 
potential of confounders and bias in this study it is not possible to draw many 
specific conclusions.  The report does add to the body of evidence that PsA 
confers greater disability than those with psoriasis alone.11  
 
These five studies reported during the latter part of my thesis have added support 
to the earlier reports that patients with PsA have significant levels of WD, 
especially patients with more active disease.  There is new evidence from highly 
selective RCT’s that anti-TNF treatment improves WD in the short term.  
 
CONCLUSION 
This systematic critical review has synthesised the current body of evidence for 
WD in PsA.  We find intermediate quality evidence that WD in PsA is high and is 
associated with longer disease duration, high health assessment questionnaire, 
high joint count, low educational level, female sex, erosive disease and manual 
work.  There is sparse low quality evidence that WD may be worse in those with 
PsA than psoriasis alone.  There is no data on WD in early PsA, the relative 
contribution of psoriasis in those with PsA or the role of other co morbidities such 
as fatigue, depression or the metabolic syndrome.  The evidence that disability at 
work is mitigated by treatment is limited to a small number of short duration 
biologics RCTs.  There are no WD data collection tools that fulfil the OMERACT 









My thesis employs retrospective (Chapter 5 and 7) and cross sectional (Chapter 6 
and 8) study designs in order to achieve its objectives.  The individual study 
designs are discussed in the methods sections of each chapter.  Methods and 
outcome measures used throughout the thesis are discussed in this chapter.  
 
Population 
Patients with PsA recruited for study in this thesis fulfil the CASPAR 
classification criteria.76  Patients diagnoses prior to the development of the criteria 
in 2006 fulfil a CASPAR criteria modified for retrospective classification of an 
existing cohort developed as part of the body of work of this thesis (Chapter 5 and 
7).77  All patients were recruited from the UK.  Differing methods of recruitment 
were used in each study and are discussed separately in each chapter.  
 
Intervention 




Work Productivity and Activity Impairment –Specific Health Problem 
(WPAI) Questionnaire 
 
The work outcome measure used throughout this thesis is the WPAI (Appendix 
1).78  The WPAI is a patient-reported quantitative assessment of the amount of 
absenteeism, presenteeism, productivity loss and general activity impairment 
attributable to a specific health problem.  The WPAI is a six item questionnaire 
asking patients to report the degree to which they experience difficulty at work 
due to a specific health problem, in this case PsA.  The six questions are;  
i) Are you currently employed? yes/no. 
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ii) During the past seven days, how many hours did you miss from 
work because of problems associated with your psoriatic arthritis?  
Include hours you missed on sick days, times you went in late, left 
early, etc., because of your psoriatic arthritis.  Do not include time 
you missed to participate in this study. 
iii) During the past seven days, how many hours did you miss from 
work because of any other reason, such as vacation, holidays, time 
off to participate in this study? 
iv) During the past seven days, how many hours did you actually 
work? 
v) During the past seven days, how much did your psoriatic arthritis 
affect your productivity while you were working?  Responses are 
made on 0 to 10 Visual Analogue Scale (VAS);  
vi) During the past seven days, how much did your psoriatic arthritis 
affect your ability to do your regular daily activities, other than 
work at a job?  As for question five responses are made on a visual 
analogue scale. 
Four main outcomes can be generated from the WPAI and expressed in 
percentages by multiplying the following scores by 100: 1) Percent work 
time missed due to PsA, ‘Absenteeism’ = Q2/(Q2 + Q4) for those who 
were currently employed; 2) Percent impairment while working due to 
PsA, ‘Presenteeism’ = Q5/10 for those who were currently employed and 
actually worked in the past seven days; 3) Percent overall work 
impairment due to PsA, ‘Productivity loss’ Q2/(Q2 + Q4) + [(1 - Q2/(Q2 + 
Q4)) × (Q5/10)] for those who were currently employed; 4) Percent 
activity impairment due to PsA Q6/10 for all respondents. For those who 
missed work and did not actually work in the past seven days, the percent 
overall work impairment due to PsA will be equal to the percent work time 
missed due to PsA.  
 
The WPAI has been chosen as the primary work measure in this thesis for a 
number of reasons.  First, the tool measures both absenteeism and presenteeism 
which are viewed as the most appropriate in health economics research.40  Second, 
the WPAI has been validated in the two closest clinical conditions rheumatoid 
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arthritis79 and ankylosing spondylitis67 and has been used in PsA.65, 80  Third, the 
WPAI reports over one week which minimises the chance of recall bias.  A 
shorter recall period may allow an instrument to be more sensitive to change.  
Furthermore this is consistent with all the other outcome measures used in this 
thesis which are also based upon symptoms over the preceding week, thus 
enabling comparison between measures over the same period of time.  Fourth, the 
WPAI was designed to be feasible and applied by post, comprising of only six 
questions.67  Fifth, the WPAI is disease specific such that work disability is 
attributed specifically to PsA.  The advantages and disadvantages of attribution 
have been discussed in the introduction.  Finally, the WPAI was identified at 
OMERACT 9 to be one of five promising candidates that should be evaluated 
further.66 
 
The WPAI does have some limitations.  It only applies to those in employment 
and may therefore exclude some economically active individuals such as carers, 
homemakers and volunteers.  The questionnaire comprises only six questions 
which does improve feasibility but means it does not include information on 
potential contextual factors such as work type, work adaptations and employer 
influences.  This data has been captured in an additional study questionnaire 
(work questionnaire see below). 
 
Work Questionnaire 
In order to address some of the weaknesses of the WPAI and collect data on 
potential confounding and contextual factors of WD, a novel work questionnaire 
has also been included in the data collection for chapter eight, objective five 
(appendix 2). This form includes information on work type, reasons for not 
working, adaptations made at work, perceived helpfulness of the employer (Likert 
scale), and any non-medication related work therapy such as physiotherapy or 
occupational therapy. 
  
The Health Assessment Questionnaire- HAQ 
The health assessment questionnaire is a measure of physical function used in rheumatoid 
arthritis and is an increasingly accepted and validated measure in PsA.81-84  The health 
assessment questionnaire is a patient-reported assessment of ability to perform tasks 
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related to daily living.  Twenty questions are asked in eight domains; dressing and 
grooming, rising, eating, walking, hygiene, reach, grip and activities (Appendix 3).  
Patients rate their ability to perform tasks in these areas from “no difficulty” to “unable to 
do”, over the prior week.  The overall score is reported as a score between 0 and 3.81  
Patients can be classified as; mildly disabled (0-1), moderately disabled (>1-2) or 
severely disabled (>2-3).  Observational studies of patients with PsA have demonstrated 
functional disability to be significantly higher than that of the healthy population and 
comparable to rheumatoid arthritis.82, 85  The longitudinal course of physical function in 
PsA as an outcome has been studied previously focusing on the transition between 
predefined health assessment questionnaire states.83, 84  Older age, female sex, longer 
disease duration, and higher number of inflamed joints all predict transition between 
disability states as measured by the health assessment questionnaire.83  Female sex is 
associated with an increased likelihood of progression of disability and increasing age 
associated with a decreased likelihood of improvement.83  Smoking and delay to 
diagnosis are associated with higher health assessment questionnaire in established 
disease.86  The Minimally Important Difference (MID) of health assessment questionnaire 
is estimated to be between 0.1387 and 0.3588, 89.  The health assessment questionnaire has 
been collected for this thesis to investigate the relationships of physical function with 
WD. 
 
The EuroQol 5-domain EQ5D 
The European quality of life 5-domain (EQ5D) is patient reported outcome (PRO) 
measuring of health related quality of life (HRQol) (Appendix 4).90  The 
questionnaire consists of five descriptive questions and a visual analogue scale 
(EQ5Dvas) from 100 (best imaginable health) to 0 (worst imaginable health).  A 
single summary index is generated using a valuation index specific to the UK.  
The performance of the EuroQol (EQ5D) has been assessed in patients with 
psoriasis91 and has been used in observational studies of PsA48, 92, 93.  It 
distinguishes well across levels of PsA severity and demonstrates utility gain in 
patients started on anti-TNF therapy within the first few weeks, sustained over 
time.93  The EQ5D has been collected for this thesis to investigate the 
relationships of general HRQol with WD. 
 
The Dermatology Quality of Life Index (DLQI) 
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The Dermatology quality of life index (DLQI) is a measure of disability 
experienced by patients with dermatological conditions.94  The DLQI is a 10 item 
patient reported questionnaire which asks patients to attribute the effects of their 
skin condition on domains of quality of life including, work, leisure activities, 
personal relationships and embarrassment over the previous week (Appendix 5).  
Responses are scored 0- ‘not at all’, 1- ‘a little’, 2- ‘a lot’, 3- very much’ resulting 
in a score from 0-30.  It has been validated in psoriasis with evidence for its 
discrimination and responsiveness as reviewed by Mease in 2011.72  The DLQI 
has been collected for this thesis to investigate the relationships skin specific 
HRQoL with WD. 
 
The Functional Assessment of Chronic Illness Therapy- Fatigue (FACIT-
fatigue) 
The functional assessment of chronic illness therapy- fatigue (FACIT-fatigue) is a 
13 item quantitative measure of fatigue over the prior week (appendix 6).95  
Responses are on a five point Likert scale of 0- ‘not at all’, 1- ‘a little’, 2- 
‘somewhat’, 3- ‘quite a bit’, 4- ‘very much’, the resulting score thus ranges from 
0-52.  Originally developed for use in anaemia the FACIT-fatigue has evidence 
for its feasibility, reliability, responsiveness and construct validity in PsA.8, 96  
FACIT-fatigue has been collected for this thesis to investigate the relationship of 
fatigue with WD. 
 
Global Scores 
Patient global scores compliment other scores by encompassing impacts of 
disease such as systemic feelings of ill health and the burden and side effects of 
treatments.  A recent study undertaken by the GRAPPA network set out to assess 
the validity and additional utility of domain specific visual analogue scores for 
Global, Skin and Joint disease activity in PsA (appendix 7).97  319 patients from 
18 centres in 10 countries participated. Global visual analogue scores, 66/68 joint 
counts, skin scores (Psoriasis Area and Severity Index- PASI) and depression 
scores (Hospital Anxiety and Depression Score- HADS) were assessed at baseline 
and one week later.  Respondents are asked to rate their skin, joints or ‘in all the 
ways your PsA affects you’ by marking a line on a visual analogue scale.  Scores 
are rated on a horizontal line of 100mm where 0 represents ‘no symptoms’ and 
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100 represents ‘very poor, severe symptoms’.  The global visual analogue score 
was found to be reliable and correlate closely with joint and skin scores.  The skin 
and joint visual analogue scores offered additional utility when domain severity 
diverged.97 Visual analogue scales have been collected for this thesis to 
investigate the relationships of WD with measures of disease activity.  
 
Background form 
Demographic data has been included on a background form (appendix 8).  
Demographic and socioeconomic factors are known to influence WD in related 
diseases such as rheumatoid arthritis and ankylosing spondylitis.66  The form for 
collecting demographic information was developed specifically for this study and 
includes data on sex, education, smoking and alcohol use, ethnicity, disease and 
symptom duration and co-morbidities.  
  
Radiology 
Radiographs of the hands and feet have been scored with the Psoriatic Arthritis 
Ratingen System (PARS) validated for use in PsA.98  This is the only scoring 
system specifically developed for use in PsA rather than adapted from use in 
rheumatoid arthritis.  It includes a measure of bone proliferation which is the only 
radiographic feature specific to PsA in the CASPAR criteria addition to the ‘truth’ 
domain of the OMERACT filter.76  The OMERACT filter is an internationally 
agreed set of criteria against which an outcome measure can be assessed. A 
measure is endorsed by OMERACT once all criteria are met.99 The filter 
comprises ‘truth’, does it measure what it intends to measure without bias 
(comprised of face, content, construct and criterion validity), discrimination 
(comprised of reliability and responsiveness) and feasibility (within the 
constraints of time, money and practicality).   
   
Disease Activity in Psoriatic Arthritis (DAPSA) 
The Disease Activity in Psoriatic Arthritis (DAPSA) is a clinical composite 
disease activity measure.  The DAPSA was derived from the Disease Activity in 
Reactive Arthritis (DAREA) which was a score derived from; a 28 tender and 
swollen joint count, C-reactive protein (CRP), patient global and pain visual 
analogue scores summed together.100  The DAREA was adapted through 
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substitution of the 28 joint count used in the Disease Activity Score 28 (DAS 28) 
with the 66/68 tender and swollen joint count to form the DAPSA.100, 101  This 
extended joint count accommodates the varied joint involvement of peripheral 
PsA and is advocated by OMERACT and GRAPPA.42  The joints included in the 
66/68 joint count are; distal interphalangeal (DIP’s), proximal interpalangeal 
(PIP’s), metacarpaophalangeal (MCP’s), wrists, elbows, glenohumeral, 
acromioclavicular, sternoclavicular, temporomandibular, hips, knees, ankles, 
midtarsals, metatarsophalangeal, and the PIP’s of the toes.  There is evidence for 
its feasibility, acceptability, responsiveness and construct validity in PsA.101, 102  
There are other composite measures with evidence for their validity for use in PsA 
including the Composite Psoriatic Disease Activity Index (CPDAI) and the 
Psoriatic Arthritis Joint Activity Index (PASJAI) reviewed by Mease.72  The 
DAPSA was chosen for this study because it was felt to offer the best balance 
between feasibility and evidence for its validity in PsA.  Feasibility is a critical 
consideration when undertaking longitudinal observational studies following large 
numbers of patients at repeated follow up intervals.  The DAPSA typically takes 
less than 5 minutes to obtain.  Skin assessment did not reach a significant level in 
the principle component analysis therefore the DAPSA does not include a skin 
score which further improves its feasibility.  It may be argued that the DAPSA 
does not fulfil the OMERACT filter for truth because it does not include measures 
of skin, entheseal or spinal involvement and therefore does not encompass all 
aspects of PsA.  For the purposes of my thesis the domain of skin will be 
measured a separate patient reported skin visual analogue score and the spinal and 
entheseal domains under the umbrella of patient global visual analogue score (see 
Global Scores).  This decision to use the DAPSA is supported by a recent 
comparison of the CPDAI, DAPSA and other composite measures in which the 
DAPSA performed comparably in discriminating between high and low disease 
activity.103  The DAPSA has been collected for this thesis to investigate the 
relationships of WD with disease activity. 
 
Reporting 
The systematic review has been conducted and reported in accordance with the 
Preferred Reporting Items for Systematic reviews and MetaAnalyses- PRISMA 
recommendations.104  The observational manuscripts have been conducted and 
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reported in accordance with the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement.105  The STROBE statement is a 
checklist of 22 items that was developed in order to strengthen the reporting of 
observational studies.  
  
Database and research unit 
The research unit is based at the RNHRD. All study data is held on a database in 
this unit on a password protected computer in a secure room.  The database is 
supervised by a data protection officer and Caldecott guardian.  All the 
questionnaires and forms used in the studies included in this thesis are paper 
based.  The software used to scan is ‘Teleform’, a Hewlett Packard product 
developed by Cardiff Sofware 1991.  Forms are created in readable formats and 
when completed they are then scanned into a password protected Microsoft access 
database 2003.  A pdf form is made simultaneously and stored separately to 
maintain a duplicate of the original data.  The specificity of the scanning is set to 
99%, thereby flagging any queries for manual confirmation.  The study master 
files containing all the regulatory approvals and communications are held securely 
at the research unit.   
 
Data entry/ storage 
Data entry is audited monthly against the pdf originals for missing data.  Missing 
data points are then confirmed manually with each site.  If an expected 
questionnaire or data collection form is not received up to two reminders are sent 
to each participant.  If no reply is received the data is recorded as missing.  
Confirmation of the accuracy of the data scanning process was made by auditing 
the data from 100 EQ5D questionnaires against the original pdf for misreading.  




A database and administrative team were put together from the existing RNHRD 
research group, Charlotte Cavill as database manager/ data security officer, 
Mandy Knight and Austin Smith as database administrators and Nina Griffith as 
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research nurse.  Study data is sent to the database team for uploading to the access 
database using the scanning ‘Teleform’ process.  
 
Analysis 
Analyses for chapters our and five were undertaken in SPSS versions 17-20 by the 
author.  Analyses for chapters six and seven were undertaken by Dr G Shaddick 
(Reader in Mathematics, University of Bath) in statistics package R and this is 
accredited accordingly.  Specific statistical tests used are discussed in the methods 
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Full ethical approval was given for research conducted in this thesis including the 
collection and storage of the clinical and radiological data (Table 1).  
 
Table 1: Regulatory Approvals 
 
Objective Regulatory body Authorisation 
number 
 








Objectives 4b, 5 
 










National Research Ethics Committee (NREC) 
Royal National Hospital for Rheumatic Diseases (RNHRD) 
National Institute for Health Research (NIHR) 




Having addressed the methods used in this thesis we will now move on to the 
individual studies that answer each of the objectives.  The first step is to classify 
an existing cohort of patients with PsA according to the CASPAR criteria, 
modified for retrospective application (objective 2).  Once this has been achieved 
a cross sectional study can be undertaken on this group of patients to examine the 





CHAPTER IV  
 
 
CLASSIFICATION OF AN EXISTING COHORT OF 
PATIENTS WITH PSORIATIC ARTHRITIS USING A 
THE CASPAR CRITERIA 
 
In order to validate a measure of work disability a well classified cohort of 
patients with PsA was required to study.  Until recently there has been no 
international consensus on a classification criterion for PsA.  In 2006 a 
classification criteria was agreed upon however this was designed for prospective 
use.76  Since 1989 patients with a clinical diagnosis of PsA at the Royal National 
Hospital for Rheumatic diseases have been followed in a large longitudinal 
observational study.  This current chapter describes a modification of the 
CASPAR criterion to enable the retrospective classification of this existing 
cohort.  This report has been published and the following is taken from that 
publication resulting in a small amount of repetition. 77  
 
INTRODUCTION 
Psoriatic arthritis (PsA) is a distinct chronic inflammatory arthritis associated with 
psoriasis.  There are a variety of clinical phenotypes resulting in historic 
variability in case definition, potentially confounding research.  The original 
classification criteria were developed by Moll and Wright16 however despite the 
proposal of a number of other criteria 106 none have been universally accepted.107  
In response to this the CASPAR study group developed a classification criteria 
specifically for use in clinical research.76  Their large prospective, multinational 
study found the CASPAR criteria to be simple to use and demonstrated a 
sensitivity and specificity of 0.914 and 0.987 respectively.  Subsequent studies 
confirmed these findings. 108-111 
 
Whilst the CASPAR criteria can be used with confidence in prospective trials, to 
my knowledge its performance when used retrospectively has not yet been 
assessed.  Much of the observational research in PsA relies on cohorts established 
prior to the development of the CASPAR criteria.  It is essential that such cohorts 
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can be appropriately classified.  I have set out to investigate the feasibility and 
performance of the CASPAR criteria when used to retrospectively classify an 
existing study cohort.  
 
PATIENTS AND METHODS 
The CASPAR criteria were applied to records from 480 patients from the 
RNHRD PsA cohort and 100 consecutive controls with inflammatory arthritis 
from a general rheumatology clinic.  The CASPAR criteria consist of confirmed 
inflammatory articular disease (joint, spine or entheseal) with at least three points 
from the following features;76  
1. Current psoriasis (2 points) 
2. A personal or family history of psoriasis (1 point) 
(Unless current psoriasis is present, first or second degree relative) 
3. Dactylitis (1 point) 
(Current or prior history recorded by a Rheumatologist) 
4. Juxtaarticular new bone formation, hands or feet, (1 point)  
(Ill-defined ossification near joint margins- excluding osteophyte 
formation- on plain hand and feet radiographs) 
5. Rheumatoid factor negativity  (1 point) 
6. Psoriatic nail dystrophy (1 point) 
(Onycholysis, pitting, and hyperkeratosis observed on current 
physical examination) 
I adapted this score for retrospective use from medical records in such a way that; 
‘inflammation’ and ‘current psoriasis’ were scored if they had ever been 
confirmed by a Rheumatologist in the PsA clinic.  This study was conceived, led 
and reported by myself.  To optimise feasibility once three points had been scored 
(indicating PsA according to the CASPAR criteria) the records were not further 
scrutinised.  Two raters reviewed all records (Myself and co-author Dr Luisa 
Costa).  Inter-rater reliability was assessed based on duplicate scoring of twenty 
records.  The diagnostic gold standard was expert clinical diagnosis by a clinician 
with longstanding expertise in PsA.76, 108-110  In cases of doubt where the clinical 
diagnosis was of PsA and did not fulfil CASPAR criteria the records and 
radiology were reviewed in full for consensus (Myself, Dr Luisa Costa and 
Professor N McHugh).  Two sensitivity and specificity analyses were performed.  
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The first excluded those with a clinical diagnosis of PsA but who did not have 
sufficient data available to confirm the classification with the CASPAR criteria.  
The second analysis was performed on all records including those with missing 
data.   
 
RESULTS 
Nine case records were missing or destroyed leaving 471 cases from the PsA 
cohort.  On review, 456 cases had PsA.  The diagnosis had changed over time in 
fifteen cases and they were entered into the control group.  Of the 115 controls 96 
had rheumatoid arthritis, five OA, three reactive arthritis (ReA), three 
seronegative arthritis, three undifferentiated arthralgia, two ankylosing 
spondylitis, one spondyloarthritis and two systemic sclerosis (demographics table 
1).  Four percent of the control group had current or personal history of psoriasis 
consistent with current prevalence estimates of between 0.6%-4%.112 28 (4.6%) of 










 n=115  
Mean (SD) 
Age year (n=456) 57.4 (13.2) 65 (+/-14.1) 
Age onset of Arthritis years (n=456) 39.5 (13.8) 56.8 (+/- 14.4) 
Age at onset of Psoriasis years (n=456) 30.3 (15.4) N/A 
Sex- Female % 53.1% 73% 
Rheumatoid Factor  +ve % (n= 416) 2.9% 64% 
Anti-Cyclic Citrullinated Peptide  +ve % (n=363) 1.3% 43% 
Phenotype (n=316)   
 Distal interphalangeal joint (DIPJ) 0.3%  
 DIPj and Polyarthritis 0.3%  
 Monoarthritis 1.7%  
 Mutilans 1.9%  
 Oligoarthritis 22%  
 Oligoarthritis and Spondyloarthritis 3.9%  
 Polyarthritis 59.4%  
 Polyarthritis and Spondyloarthritis 8.5%  
 Spondyloarthritis 1.9%  
 
 
Of the 456 patients with a physician diagnosis of PsA eight did not fulfil 
CASPAR criteria.  For only one of these information regarding all the CASPAR 
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criteria was available.  For a further seven patients either no radiographs or no 
RhF test results were available to enable a complete assessment.  Sensitivity and 
specificity were 99.7% and 99.1% respectively.  Sensitivity remained high even 
after inclusion of the seven case records with missing data (Sensitivity 98.2%, 
Specificity 99.1%).   
 
The objectivity of the CASPAR assessment resulted in excellent inter-rater 
reliability.  Of the twenty records reviewed there was full agreement in eighteen 
cases.  Both raters also identified the same two records as cases of doubt for 
consensus review.  Both raters found the CASPAR to be easy and quick to use. 
52% of the PsA cases fulfilled criteria based on current psoriasis, a negative 




The CASPAR criteria could be applied prospectively to established research 
cohorts but waiting for all the patients to attend clinic would take years.  The 
ability to use a classification tool retrospectively is therefore important.  We have 
found the CASPAR criteria to be easy and practical to use for three reasons.  First, 
the majority of cases reached the required 3 points quickly from inflammation, 
current psoriasis and a negative rheumatoid factor.  Second, the objectivity of the 
criteria made inter rater reliability high with minimal training.  Third, removing 
the requirement to scrutinise the records after sufficient points had been reached 
further improved the feasibility.  Finally, missing data points are a reality of 
observational research however the sensitivity and specificity were found to be 
similar to previous reports 76, 108-110 even when data points were missing. 
 
This study is potentially weakened by three factors. First, there is the lack of a 
gold standard which has been a concern in prior reports. The approach involving 
experienced physicians diagnosis is a recognised method113 which has been 
applied in prior studies.108-110  Second, through modification of the CASPAR 
criteria to allow ‘current psoriasis’ and inflammation to be scored at any time 
rather than at the same clinical assessment we have potentially increased the 
sensitivity.  The initial sensitivity of the criteria was 91% reported by Taylor76 
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however subsequent reports have all estimated the sensitivity to be between 97 
and 100% 108-110 limiting the degree to which we can overestimate it.  Furthermore 
specificity is of greater importance when classifying a research cohort.  Finally, 
we have not compared the performance of the CASPAR criteria to other criteria.  
These comparisons have already been made elsewhere in the literature 76, 110, 114 
and the purpose of this study was to assess whether the feasibility and 
performance characteristics were maintained when the CASPAR criteria were 
used retrospectively.  
 
In conclusion, this study demonstrates that the feasibility, specificity and 
sensitivity of the CASPAR criteria are maintained when adapted for retrospective 
use to classify an established research cohort from medical records even in those 
with missing data.  This modification of the CASPAR criteria for retrospective 
use addresses objective 2 of this thesis.  I will now describe a cross sectional study 
undertaken to address objective 3 of this thesis, to explore the validity of the 






CHAPTER V  
 
 
WORK DISABILITY IN ESTABLISHED PSA- A 
PRELIMINARY VALIDATION OF THE WORK 
PRODUCTIVITY AND ACTIVITY INDEX 
 
This current chapter relates to objective three of my thesis, to examine the 
feasibility, construct and discriminative validity of the Work Productivity and 
Activity Index- Specific Health Problem (WPAI) questionnaire in PsA.  This 
study has been reported resulting in a small amount of repetition.115  
 
BACKGROUND 
Psoriatic arthritis is a distinct inflammatory arthritis associated with psoriasis.  
PsA is a heterogeneous disease; patients have skin and joint disease but may also 
have manifestations such as enthesitis, axial disease, uveitis, the metabolic 
syndrome and other less well defined factors related to long term inflammation 
such as fatigue.  All these elements combine to have a significantly detrimental 
effect on physical function and quality of life.82  Work is of central importance to 
patients and it is now well recognised that Work Disability (WD) is an important, 
patient centred quality of life outcome that needs further investigation.116  WD is 
an umbrella term encompassing a spectrum of disability ranging from 
presenteeism (reduced effectiveness at work) through to absenteeism and 
unemployment.  There is no universally accepted measure of WD although a 
number have been proposed and it is a subject of current interest within the 
Worker Productivity Special Interest Group (WP-SIG) of Outcome Measures in 
Rheumatology (OMERACT).117  
 
Unemployment and WD in PsA is high, with estimates for each ranging between 
16-39% and 20-50% respectively.41  Preliminary evidence suggests that longer 
disease duration, worse physical function, high joint count, low educational level, 
female sex, erosive disease and manual work are all associated with increased 
WD in PsA41  However accurate interpretation of predictive factors is hampered 




The Work productivity activity index specific health problem questionnaire 
(WPAI) is a patient reported questionnaire used to assess the impact of disease on 
work productivity. 78  The questionnaire has been validated in a number of chronic 
conditions including ankylosing spondylitis67 and rheumatoid arthritis79 and has 
been used in psoriasis.65, 80  I set out to assess the feasibility, construct and 
discriminative validity of the WPAI in patients with PsA.  
 
METHODS 
This cross sectional validation study was undertaken as part of the Long term 
Outcomes in Psoriatic Study I (LOPAS I). Since 1989 patients with PsA at the 
Royal National Hospital for Rheumatic Diseases, Bath, UK have been included in 
the longitudinal observational study with prospective collection of clinical 
outcome measures during their routine clinical follow up and biannual postal 
patient reported outcome measures.  This present validations study was conceived, 
led and reported by myself.  Adults with PsA of any disease duration are eligible 
for inclusion in the study.  All participants fulfilled the ClASsification for 
Psoriatic Arthritis- CASPAR criteria.77  All 380 patients participating in the postal 
study were sent the following questionnaires; health assessment questionnaire, 
Patient Global Visual analogue scale (PtG), EuroQol (EQ5D), Dermatology Life 
Quality Index (DLQI), the Functional Assessment of Chronic Illness Therapy 
Fatigue score (FACTIT-F) and the WPAI.  
 
The WPAI questionnaire asks patients to report the degree to which they 
experience difficulty at work due to a specific health problem, in this case PsA.  
There are six questions in total; 1 = currently employed- yes/no; 2 = hours missed 
due to PsA; 3 = hours missed for other reasons; 4 = hours actually worked; 5 = 
degree to which PsA is affected productivity while working using a 0 to 10 Visual 
Analogue Scale (VAS); 6 = degree to which PsA is affects productivity in regular 
unpaid activities (using a VAS).  The recall period for questions 2 to 6 is seven 
days. Four main outcomes can be generated from the WPAI and expressed in 
percentages by multiplying the following scores by 100: 1) Percent work time 
missed due to PsA, ‘Absenteeism’ = Q2/(Q2 + Q4) for those who were currently 
employed; 2) Percent impairment while working due to PsA, ‘Presenteeism’ = 
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Q5/10 for those who were currently employed and actually worked in the past 
seven days; 3) Percent overall work impairment due to PsA, ‘Productivity loss’ 
Q2/(Q2 + Q4) + [(1 - Q2/(Q2 + Q4)) × (Q5/10)] for those who were currently 
employed; 4) Percent activity impairment due to PsA Q6/10 for all respondents.  
For those who missed work and did not actually work in the past seven days, the 
percent overall work impairment due to PsA will be equal to the percent work 
time missed due to PsA.  
 
Statistical analysis was undertaken in SPSS v17.  Descriptive statistics were used 
to provide demographic information.  Due to the non-Gaussian distribution of the 
data nonparametric tests were used.  Spearman’s correlation coefficient was used 
to estimate the correlation of the WPAI with other outcome measures validated 
for use in PsA72 as an estimate of construct validity.  Mann-Whitney U was used 
to assess whether the WPAI was able to discriminate between better or worse PsA 
defined by the median of each outcome in order to estimate discriminative 
validity.  Using the OMERACT model feasibility was determined by ease of 
application, given the constraints of time, money and interpretability. 
 
This study was approved through the Bristol research ethics committee and 







Two hundred and seventy patients responded (71.0%).  Ninety-five percent 
fulfilled CASPAR criteria for PsA, 50% were male, mean age was 57 (standard 
deviation- SD 13.0), mean PsA duration was 17years (SD 10.6) and the mean 
Psoriasis duration was 25years (SD 14.9).  
 
Outcome measures are reported in Table 1. 190 patients were of UK working age 
(18-65years) and 131 were still working.  Of those still working absenteeism, 
presenteeism and work productivity loss secondary to PsA over the last week 
were 4.7%, 21.1% and 24.0% respectively.  Of the fifty nine patients of working 
age not working fourteen were not working because of their PsA, twelve were not 
working for other reasons and thirty three were retired. 
 
Table 1 
Comparison of disease outcome measures by working status 
 








Working age  
not working 
(n=59) 
HAQ Global Median (IQR) 2.0  (1.0) 2.0 (1.0) 2.0 (1.0) 2.0 (2.0) 
HAQ DI Median (IQR) 0.62 (1.2) 0.62 (1.13) 0.62 (1.00) 1.00 (1.62) 
Pain VAS Median (IQR) 2.6 (3.8) 2.60 (4.8) 2.2 (3.1) 4.4 (4.70) 
EQ-5Dvas Median (IQR) 70.0 (35.0) 70.0 (25.0) 75 (35.0) 60 (44.0) 
EQ5Dindex Median (IQR) 0.69 (0.21) 0.69 (0.21) 0.73 (0.18) 0.60 (0.32) 
DLQI Median (IQR) 2.0 (3.0) 2.0 (3.0) 2.0 (3.0) 2.0 (6.75) 
FACIT-fatigue Median (IQR) 38.0 (19.5) 18.2 (16.0) 20.6 (14.0) 17.3 (19.0) 
 
Health assessment questionnaire (HAQ), disease index (DI), visual analogue score (VAS), Euroqol 5 domain (EQ5D), 
dermatology quality of life index (DLQI), functional assessment of chronic illness therapy fatigue (FACIT-fatigue), Inter 
quartile range (IQR),  
 
We found the WPAI to be low cost (paper and postage costs only) and quick to 
apply (six questions).  We also found the WPAI easy to analyse and interpret.  
The results are expressed as a percentage over the preceding week, rather than 
alternative tools that report hours absent from work which is a harder measure to 




Correlations with other outcome measures and discrimination between better and 
worse PsA states are reported in table 2.  Statistically significant Spearman rank 
correlation coefficients are reported are stratified as strong (>0.60), moderate 
(0.40 to 0.59) and weak (0.20 to 0.39).118 Absenteeism demonstrated weak 
correlation with health assessment questionnaire, EQ5Dindex and FACIT-fatigue.  
Presenteeism showed strong correlation with the patient global visual activity 
scale/ health assessment questionnaire, EQ5Dindex and FACIT-fatigue, moderate 
correlation with pain and weak correlation with the DLQI.  Work productivity 
loss showed strong correlation with patient global visual activity scale/ health 
assessment questionnaire, EQ5Dindex and FACIT-fatigue and moderate 
correlation with pain. 
 
Table 2 
WPAI correlation with other measures (construct validity) and discrimination 










WPAI  Correlations with 
other measures 
Spearman R correlations;  
Construct validity 
Absenteeism 0.16 0.13 0.39* -0.28* -0.1 0.27* 
Presenteeism 0.54* 0.43* 0.60* -0.63* 0.25* 0.64* 
Productivity loss 0.56* 0.41* 0.65* -0.65* 0.15 0.64* 
WPAI discrimination 
between better and  
worse health status,  
(median of each measure) 
Mann Whitney U-  Z score 
Discriminative validity 
Absenteeism -0.07 -1.86 -2.59* -0.39* -0.28 -2.26 
Presenteeism -5.38* -4.53* -6.05* -6.32* -2.31 -6.33* 
Productivity loss -4.72* -4.49* -5.74* -6.13* -1.13 -6.11* 
* p<0.05 
 
Work productivity and activity index (WPAI), Health assessment questionnaire (HAQ), disease index (DI), visual analogue 
score (VAS), Euroqol 5 domain (EQ5D), dermatology quality of life index (DLQI), functional assessment of chronic 
illness therapy fatigue (FACIT-fatigue) 
Spearman correlations-estimate of construct validity by correlating with other measures of disease activity 
Mann Whitney U- Z score- estimate of responsiveness through differentiation between high and low disease activity states 




The Mann-Whitney U test demonstrated the WPAI measurement of presenteeism 
and productivity loss was able to differentiate between better and worse PsA 
states as measured by patient global activity, health assessment questionnaire, 
EQ5D and FACIT fatigue (Table 2).  For example when patients were grouped 
into those with better physical function (health assessment questionnaire score 
below the median) and those with worse physical function (health assessment 
questionnaire score above the median) those with better physical function reported 
less presenteeism (8.9% SD 13.9 versus 30.9% SD 22.2).  The measure of 
absenteeism differentiated between better and worse PsA states only in the 




To my knowledge this is the first attempt to validate a work outcome measure in 
PsA.  Whilst a variety of WD measures are available6 I chose to investigate the 
WPAI for three reasons.  First, it includes measures of both absenteeism and 
presenteeism, the two core WD measures as determined at OMERACT 10.6  
Second, the recall period is one week, as are most of the other outcomes in this 
study.  To assess the construct validity of the WPAI we have conducted 
correlation coefficients with other outcome measures therefore it is crucial the 
measures assess the same period of time.  A short recall time minimises the risk of 
recall bias and has a greater potential for detecting change in a condition subject 
to relapse and remission, two desirable features if the intention is to apply the tool 
to study change in WD over time and the effect of treatment. 119  Third, there is 
good evidence for the validity of the WPAI in the two most closely related 
conditions rheumatoid arthritis79 and ankylosing spondylitis67 and it has also been 
used in psoriasis.65, 80 
 
I have found the WPAI easy and quick to apply, low cost and readily 
interpretable, thus fulfilling the OMERACT criteria for feasibility.  The WPAI 
estimates of presenteeism and productivity loss correlated with health assessment 
questionnaire, EQ5D and FACIT fatigue.  The correlation with DLQI was either 
absent or poor but this may relate to the skin disease characteristics of our cohort.  
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The majority had mild skin involvement and a small minority had marked skin 
disease.  Absenteeism showed weaker correlations as is the case in similar studies 
in rheumatoid arthritis79 and ankylosing spondylitis67.  In the present study this 
finding may be related to the smaller numbers reporting a period of absenteeism.  
A current leading model of disability at work suggests individuals pass through 
escalating disability states from presenteeism, absenteeism, temporary 
unemployment to permanent unemployment or retirement.66  Under this model we 
would expect periods of presenteeism would be more common and lead on to 
absenteeism if disease deteriorates or adaptation is not possible.  
 
I report moderate work disability in PsA patients of working age.  Direct 
comparison of disability levels with other diseases such as rheumatoid arthritis 
and ankylosing spondylitis cannot be made without inclusion of locally matched 
disease controls.  PsA patients in this study all had established disease and are 
from a well classified single secondary care centre in the UK.  
 
The findings of this study should be interpreted taking into account some 
methodological considerations.  The Spearman is a measure of association only 
and does not infer causality. This is a cross sectional study and the recall period of 
the outcome measures used is only one week introducing the possibility that 
longer term disability or fluctuations in disease activity may not have been 
captured (discussed further in the discussion section of this thesis). The WPAI 
asks patients to attribute their WD to psoriatic arthritis rather than their general 
health which may be difficult for patients to do.  However if the goal is to study 
the effect of disease specific treatment on WD a disease specific tool is 
desirable.119  Furthermore in a study of WD in rheumatoid arthritis results were 
participants were similar for WD in general and WD secondary to rheumatoid 
arthritis.120  The cohort in our study had established disease with a mean age of 
(57years) and a relatively long mean PsA duration (17years), though the majority 
were still of working age (70%).  It is therefore possible our estimates of WD are 
high as the cohort is more likely to have advanced damage as a result of 
longstanding disease.  With the relative lack of participants with early disease we 
may also have an underestimated the effect of more recent inflammatory joint 
disease on WD.  Finally the study population are from a single centre in the UK 
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and the impact of country specific social security systems on disability pensions 




The findings of this study address objective three of this thesis, providing 
evidence for the feasibility, construct and discriminative validity of the WPAI in 
PsA.  Further prospective study should further validate the WPAI through 
assessment of its sensitivity to change with clinical parameters such as joint count, 
inflammatory markers and radiographic damage as well as estimate the minimally 
clinically important difference of the WPAI in PsA.  Objective 4a, identification 
of the optimal tool for the radiographic assessment of PsA in longitudinal 
observational studies will now be assessed.  The WPAI and the selected 
radiographic measure can then be applied in the cross sectional study in chapter 
seven, to assess the extent to which structural damage (objective 4b), clinical 
disease activity, demographic and social factors are associated with WD measured 




CHAPTER VI  
 
THE FEASIBILITY, RELIABILITY AND SENSITIVITY 
TO CHANGE OF FOUR RADIOGRAPHIC SCORING 
METHODS IN PATIENTS WITH PSA 
 
Investigating the association of work disability with disease severity is an 
important aspect of understanding the relationship between disease and disability.  
The definitive measure of disease severity is evidence of structural damage 
determined by radiographic damage.  There are a number of radiographic 
measures used in psoriatic arthritis but no agreement regarding which is the 
optimal measure to use in observational studies and there are no comparison 
studies upon which to base an informed decision.  This current study addresses 
objective four (a) of my thesis to assess the feasibility, reliability and sensitivity to 
change of four radiographic scoring methods in longitudinal observation studies 
of psoriatic arthritis (PsA).  This study has been reported resulting in a small 
amount of repetition.121 
 
INTRODUCTION 
The measurement of radiographic joint damage is essential in characterising 
disease severity, progression and prognosis.  Radiographic damage has been 
demonstrated in psoriatic arthritis (PsA) in both early and established disease.26, 
122  It is a core outcome measure in both randomised control trials (RCTs) for 
novel therapies as well as longitudinal observational studies and is included in the 
core set of outcomes recommended for use in PsA clinical trials by the Outcome 
Measures in Rheumatoid Arthritis (OMERACT) consortium.42 
 
Several scoring methods have been proposed for use in PsA including the 
Modified Sharp score (MSS)123, 124, the Sharp-van der Heijde modified method 
(VDH)124, 125, Modified Steinbroker (STB)126 and psoriatic arthritis Ratingen score 
(PARS)98.  With the exception of the Ratingen method these scoring methods 
were designed and validated for use in rheumatoid arthritis and subsequently 




The choice of radiographic outcome measure to use in PsA RCTs and longitudinal 
observational studies was discussed at the Group for Research and Assessment of 
Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting 2012 in Stockholm.  
There was consensus that the Sharp-van der Heijde modified was the optimal tool 
to use in RCTs (where sensitivity to change is often the most important attribute 
of the outcome measure) but the most appropriate tool for use in LOS is yet to be 
determined.  Agreement on the use of a single measure in LOS would improve 
comparison of study results between cohorts, pooling data and potentially aid 
meta-analyses.  I set out to assess the feasibility, reliability and sensitivity to 
change of four radiographic scoring methods in PsA in order to inform discussion 
on the optimal method for longitudinal observational studies. 
 
METHODS 
This study was conceived, led and reported in the journal of Arthritis Care 
Research by myself. Postero-anterior radiographs of the hands and feet from fifty 
consecutive patients commenced on anti-Tumour Necrosis Factor (anti-TNF) 
therapy for PsA at the Royal National Hospital for Rheumatic Diseases were 
included.  Radiographs taken at the point of anti-TNF commencement and two 
years prior were scored with each of the Steinbroker, modified Sharp, Sharp-van 
der Heijde modified method and psoriatic arthritis Ratingen methods.  This 
selection of participants and radiographs was designed to capture patients likely to 
have sustained active disease and thus progression of radiographic damage upon 
which the sensitivity to change of each method could be compared.  All 
radiographs included a ‘phantom phalanx’ as a reference for normal bone density.  
All selected patient’s fulfilled the Classification Criteria for Psoriatic Arthritis 
(CASPAR) criteria after retrospective assessment of case records.76 77 
 
Radiographic scoring methods 
The radiographic techniques are described briefly below and summarised in Table 
1.  The Steinbroker is a global technique that scores the joints of the hands and 
feet for soft tissue swelling or periarticular osteopenia, erosion, joint space 
narrowing, total destruction (lysis or ankylosis) on a single scale.  The Seinbroker 
was originally developed for use in rheumatoid arthritis and was modified for use 
in PsA through inclusion of the distal interphalangeal joints (DIPJs).126  The 
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modified Sharp and Sharp-van der Heijde modified methods are composite 
methods that score erosion and joint space narrowing separately and then are 
summed together in a total score.  The Sharp-van der Heijde method was 
originally developed for use in rheumatoid arthritis then modified for use in 
PsA.124, 125  The modified Sharp method was again adapted from the original 
method used in rheumatoid arthritis123.  The method I have used in this study is 
the same as that described by Ravindran et al. with the addition that I have 
included the feet as originally described by van der Heijde.26, 127  Finally the 
psoriatic arthritis Ratingen method  is the only method to be developed 
specifically for use in PsA.98  The psoriatic arthritis Ratingen method is a 
composite method that scores erosion and bony proliferation characteristic for 
PsA which are then summed in a total score.  
 
Radiographic methods 
Standard antero-posterior radiographs of the hands and forefeet were taken on to 
Kodak DirectView phosphor storage plates. Directly after the images were 
captured the phosphor plates were scanned and digitised using the Kodak 
DirectView CR 950 system. Images were then viewed and scored on the 
Centricity Web viewer (V3.0.10) on a standard Hewlett Packard monitor (1440-
900 pixel spacing) with the images preserved at the original 1:1 ratio, all other 
viewing tools were allowed.  
 
Reading strategy 
Two readers, WT (myself) and DJ (co-author Dr Deepak Jadon) trained in the 
four scoring methods. Using two readers reduces the impact of potential reading 
errors or bias that can arise from a from a single reader or scoring by consensus 
where a senior assessor may influence the reading of the junior member.128  The 
training in scoring methods involved pre-study training in the precise definitions 
of radiographic findings of PsA as described by Taylor et al. 24, literature review 
of each method, contact with the original authors for clarification where required, 
then practice with supervision and discussion with an experienced 
musculoskeletal radiologist (Co-author Dr Graham Robinson) over a two month 
period.  To determine reliability, ten sets of hand and feet radiographs were scored 
by both WT and DJ with all four techniques in random order to assess inter-rater 
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reliability, and then scored one month later to estimate intra-rater reliability.  The 
remaining 40 radiographs were then scored (20 by WT and 20 by DJ) with the 
prior score and radiographs available to optimise sensitivity to change.  An 




Statistical analysis was performed by Dr G Shaddick, department of mathematics, 
University of Bath, UK. Demographic data was analysed using descriptive 
statistics.  Feasibility was estimated using the average time taken to score each 
method.  Measurement error was estimated by re-scoring ten films by the same 
rater (intra-rater reliability) and by the other rater (inter-rater reliability).  
Differences are reported as recommended using both intra-class correlation 
coefficients (ICC) and visually by plotting the difference in change of scores 
against the mean change by both raters (Bland-Altman plots).129 
 
Sensitivity to change is reported using multiple methods to allow comparison with 
prior reports.  A two-way analysis of variance was performed with an interaction 
between patient and time leaving a residual from which the Standard Error of the 
Mean (SEM) could be estimated.  The Standardised Response Mean (SRM) is a 
unit-less expression of change calculated as the ratio of the mean difference 
between baseline and follow up score divided by the standard deviation of this 
difference.  An SRM of >0.8 is considered to have a high potential of detecting 
change.  I also report the Smallest Detectable Change (SDC) defined as the 
smallest difference that can be detected over and above measurement error.130  A 
similar method of reporting this is the Smallest Detectable Difference (SDD).  
The SDD is a less appropriate method to use in this study because I have assessed 
radiographs with the prior film and score available meaning the assessments 
cannot be considered to be truly independent.128  In this instance the SDD will 
overestimate the measurement error, however, I have reported the SDD to allow 
for comparison with prior reports. I also report the SDC and SDD as a percentage 




The study was approved by the Bath Research Ethics Committee and has been 
conducted in accordance with the Declaration of Helsinki.  All participants signed 
informed consent.  
 
RESULTS 
All patients fulfilled CASPAR criteria for psoriatic arthritis. The mean age of 
patients at the baseline assessment was 50 years (sd 12.1; median 53 years, range 
49). The mean disease duration at baseline was 10 years (sd 8.4; median 8 years, 
range 29). The mean interval between radiographs was 25 months (sd 9.6; median 
26 months, range 36). The mean (sd) baseline score for the Steinbrocker, psoriatic 
arthrhtis Ratingen, modified Sharp and Sharp-van der Heijde methods were 15.4 
(21.63), 13.2 (25.23), 26.3 (39.05) and 26.8 (38.25). 
 
The intra-rater reliability was high for all methods (Table 2).  The baseline inter-
rater reliability was high for the Sharp-van der Heijde, modified Sharp and 
psoriatic arthritis Ratingen scores at 0.95 (95% confidence interval (CI) 0.83-
0.99), 0.94 (95% CI 0.78-0.96) and 0.89 (95% CI 0.64-0.97), respectively.  The 
baseline inter-rater reliability for the Steinbroker was low at 0.42 (95% CI -0.21-
0.81).  Review of the 10 films revealed the source to be poor agreement on the 
presence of periarticular osteopenia in three of the ten cases.  All 50 baseline 
radiographs were therefore scored using the Steinbroker by both readers to better 
reflect the frequency of osteopenia in PsA and hence more accurately estimate the 
performance of the Steinbroker.  The baseline inter-rater reliability for all 50 
radiographs was 0.88 (95% CI 0.77-0.94). 
 
The sensitivity to change of the methods is reported in Table 3.  Using the SDC 
expressed as a percentage of the total score allows comparison between scores.  
The Sharp-van der Heijde score has the greatest ability to detect change followed 
by the modified Sharpe score, psoriatic arthritis Ratingen and Steinbroker at 1.2%, 
1.4%, 2.1% and 2.9% respectively.  The sensitivity to change of the methods 
using the SRM demonstrated the Sharp-van der Heijde followed by the modified 
Sharp score to have the greatest ability to detect change at a level approaching 
0.80.  The Steinbroker and psoriatic arthritis Ratingen showed less sensitivity to 
change with levels of 0.46 and 0.44 respectively. 
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STB 42 Joints of the hands and feet: Scale 0-4 
0 is normal. 
1 is juxta-articular osteopenia or soft tissue swelling. 
2 indicates the presence of any erosion. 
3 the presence of erosion and joint space narrowing. 
4 total joint destruction (lysis or ankylosis). 
 
N/A N/A 168 
MSS 54 joints (42 hands, 12 feet) for erosion: scale 0-5 
0 = no erosion. 
1 = one discrete erosion or involvement of < 21% of the joint are by erosion. 
2 = two discrete erosions or involvement of 21- 40% of the joint. 
3 = three discrete erosions or involvement of 41-60% of the joint. 
4 = four discrete erosions or involvement of 61-80% of the joint. 
5 = extensive destruction involving more than 80% of the joint. 
54 joints (44 hands, 10 feet) for JSN: scale 0-4 
0 = normal joint. 
1 = asymmetrical or minimal narrowing. 
2 = definite narrowing with loss of up to 50% for the normal space. 
3 = definite narrowing with loss of 51 – 99% of the normal space. 
4 = absence of a joint space, presumptive evidence of ankylosis. 
5 = widening. 
 
270 216 486 
VDH 52 joints (42 hands, 10 feet) for erosion: scale 0-5 (hands) 0-10 (feet) 
0 = no erosions. 
1= discrete erosion. 
2 = large erosion not passing the midline. 
3 = large erosion passing the mid-line. 
4 = combination of below 
5 = combination of below 
52 joints (42 hands, 10 feet) for JSN: scale 0-4 
0 = normal 
1 = asymmetrical minimal narrowing with loss of up to a maximum of 25% 
2 = definite narrowing with loss of up to 50% of the normal space 
3 = definite narrowing with loss of 50 – 99% of the normal space or subluxation 
4 = absence of a joint space, presumptive evidence of ankylosis, or complete 
subluxation. 
320 208 528 
PARS 40 joints (30 hands, 10 feet) for destruction: scale 0-5 
0 = normal. 
1 = one or more definite erosion with an interruption of the cortical plate of >1mm but 
destruction of < 10% of the total joint surface. 
2 = destruction of 11 – 25%. 
3 = destruction of 26 – 50%. 
4 = destruction of 51 – 75% . 
5 = destruction of more than 75% of the joint surface. 
40 joints (30 hands, 10 feet) for proliferation: scale 0-4 
0 = normal. 
1 = bony proliferation measured from the original bone surface of 1-2mm, or clearly 
identifiable bone growth not exceeding 25% of the original diameter of the bone.  
2 = bony proliferation of 2-3mm or bone growth between 25 to 50%  
3 = bony proliferation >3mm or bone growth >50% 
4 = bony ankylosis. 
200 160 * 360 
 
 
Steinbroker method (STB), Sharp van der Heijde method (VDH), Modified Sharp method (MSS), 








Inter/ Intra-rater reliability of each scoring method 
 
Method Range Inter rater reliability (95%CI) Intra rater reliability (95%CI) 
  Baseline Follow up Rater 1 Rater 2 
STB 
 STB (n=50) 





























































Modified Steinbroker method (STB), Sharp-van der Heijde modified method (VDH), Modified 




Figure 1.  
Bland-Altman plots to illustrate reliability of radiographic assessment 
between the two assessors. Difference in radiograph score between each 
rater plotted against mean score for each radiograph from both raters 
  
 Modified Steinbroker method (STB), Sharp-van der Heijde modified method (VDH), Modified Sharp method 
(MSS), psoriatic arthritis Ratingen score (PARS). STB original 10 plots in grey, full 50 baseline plots in black.  
  
 
The feasibility of each method was estimated based on the mean time taken to 
score each film.  The Steinbroker took the least time to score followed by the 
psoriatic arthritis Ratingen, Sharp-van der Heijde and modified Sharp at 6.2 








Radiographic assessment of joint damage in PsA is an important outcome 
measure in longitudinal observational studies, however the optimal method for 
use in this setting has not been determined and to our knowledge there are no 
reports comparing the existing methods.  I report a comparison of four 
radiographic scoring methods used in PsA to inform discussion on the optimal 
method for use in the longitudinal observational setting.  
 
In terms of feasibility each of these methods are readily available and 
interpretable as a simple summative score.  The time required to apply each 
method differs considerably in our study from 6.2 minutes to 14.6 minutes.  An 
essential attribute of a scoring method for use in longitudinal observational studies 
is that it can be readily learned and applied feasibly.  The ‘feasibility barrier’ has 
resulted in very limited radiographic data collection from observational cohorts.  
As may be expected, the Steinbroker global score is the most feasible and the time 
required to apply the composite scores is proportional to the number of areas 
scored (psoriatic arthritis Ratingen<Sharp-van der Heijde<modified Sharp).  
Whilst there is no threshold of time beyond which a score becomes unfeasible, the 
Sharp-van der Heijde and modified Sharp scores are more challenging in terms of 
time required for application in longitudinal observational studies. 
 
In this current study I have found good agreement between assessors and good 
test-re-test reliability.  The exception was osteopenia in the Steinbroker.  The 
inter/intra-rater reliability estimates for this study (baseline inter 0.88 and intra for 
both readers 0.99/ 1.0) are comparable with the original reports (inter 0.86 and 
intra for both readers 0.81/ 0.80) 126.  I have found the inter-rater reliability was 
poor (0.42) amongst the initial ten patients due to disagreement in three cases of 
possible osteopenia but rose to more acceptable levels (0.88) when applied to all 
50 patients because less osteopenia was seen.  The prevalence of periarticular 
osteopenia in PsA has not been reported but is thought to be less than rheumatoid 
arthritis131.  Our group has previously reported a strong correlation between the 
modified Sharp score and periaticular osteopenia, present in 25 of the 73 PsA 
patient hand and feet radiographs included in the study26.  Radiographic 
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osteopenia is dependent on radiographic technique, varying according to choice of 
projection, exposure and capture media, thus may vary significantly between 
time-points and radiographers.  Determining the presence of osteopenia is also 
subjective and therefore prone to variation.  For these reasons osteopenia was 
removed from a number of radiographic scoring techniques in rheumatoid 
arthritis.132  It may be argued therefore that any potential benefits of retaining 
osteopenia in a measure for use longitudinal observational studies of PsA are 
outweighed by these disadvantages. 
 
Regarding sensitivity to change we found the smallest detectable change to be 
greater than the mean change over two years in all techniques which is an 
important finding.  The smallest detectable difference/ smallest detectable change 
and minimal detectable difference are study specific (a function of mean change 
and measurement error) but are infrequently reported in trials.133  There are no 
previous reports directly comparing the sensitivity to change of the Steinbroker, 
modified Sharp or Sharp-van der Heijde in PsA.  The original psoriatic arthritis 
Ratingen method reported a minimal detectable change (calculated from the 
square root of the standard deviation of the inter-rater variance) for the total score, 
proliferation score and destruction score of 16.5, 8.4 and 11.5, respectively, which 
are comparable with our smallest detectable difference of 12.7, 5.8 and 7.3, 
respectively.98  Guillemin et al. examined the reproducibility and sensitivity to 
change of five methods including the Sharp-van der Heijde in rheumatoid 
arthritis134.  The mean change in the Sharp-van der Heijde score exceeded the 
smallest detectable difference for the total, erosion and JSN scores in their study 
(9.7, 5.8 and 7.2, respectively) yet the smallest detectable difference remains 
comparable with our study (10.8 , 7.3 and 7.3, respectively).  Sharp et al 
examined the variability of precision of the modified Sharp method among 
readers from the datasets of six studies in rheumatoid arthritis.135  Considerable 
variability between readers and the mean smallest detectable differnce was greater 
than the mean progression, as we have found in our present study.  I found that the 
smallest detectable difference/ change (normalised as a percentage of the total 
score to allow comparison) estimates were ranked as might be expected 
(Steinbroker>psoriatic arthritis Ratingen>modified Sharp>Sharp-van der Heijde). 
The smallest detectable difference/ change is largest for the global Steinbroker 
80 
 
score which assesses radiographic change as either present or absent rather than 
graded, thereby allowing less flexibility to detect change.  The Sharp-van der 
Heijde score is consistently the most sensitive to change than the score from 
which it was derived (the modified Sharp score).  Finally the psoriatic arthritis 
Ratingen score is more sensitive than the Steinbroker as it is a composite rather 
than global score allowing grading of erosion and proliferation but not as sensitive 
as the modified Sharp and Sharp-van der Heijde scores partly because it includes 
the wrist as a single joint rather than multiple small joints.  
 
Other parameters within the scoring methods are worth noting.  The soft tissue 
swelling element of the Steinbroker is an additional source of variability, 
particularly at the MTPJs there is a less clear view of the soft tissues.  The scoring 
of JSN is not specific to PsA and can occur in concurrent osteoarthritis and thus 
over-estimate progression of PsA.  The psoriatic arthritis Ratingen includes a 
measure of proliferation which was the only radiographic change sufficiently 
specific to PsA to justify inclusion in the CASPAR criteria for PsA76.  Finally, the 
composite scores preserve data separately on erosion, joint space narrowing or in 
the case of the psoriatic arthritis Ratingen proliferation, whereas such information 
is limited in a global score.  
 
The findings of this study should be interpreted in light of certain methodological 
limitations.  I have not blinded the chronological order of radiographs and have 
had the prior score available for comparison when scoring. This introduces the 
possibility of expectation bias, potentially overestimating change.  However, 
blinding to films may result in failure to detect progression. This was 
demonstrated in a study of rheumatoid arthritis which showed that blinding 
assessors to the chronology of films can introduce a measurement error that 
results in a loss of signal and hence underestimation of progression.128  A second 
study from the same group showed that expert raters agreed most when the 
sequence of films was known.136  Furthermore, two of the methods, the psoriatic 
arthritis Ratingen and Sharp-van der Heijde scores were both developed in un-
blinded studies with known chronological order and so we have applied these 
tools as they were developed.  The purpose of this present study is to identify 
which radiographic scoring method has the appropriate properties to be used in 
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longitudinal observational studies where radiographs are obtained and scored in 
routine clinical practice- thereby un-blinded and in known chronological order. It 
is not feasible to consider storing radiographs for future scoring in a blinded study 
as this would be too time consuming. Even the quickest score to perform, the 
Steinbroker, is used routinely in only one centre (Toronto psoriatic arthritis 
research unit).  Radiographs are scored un-blinded in known chronological order 
at the end of a routine clinic using a consensus approach (unpublished 
communication, Dr D Gladaman). This allows a gradual accumulation of data 
over many years that would be unfeasible to perform retrospectively. The un-
blinded approach taken in this study is therefore in keeping with the methodology 
used in the development of two of the scores and importantly is the way the tool is 
intended to be used in practice but this method does introduce the risk of 
expectation bias.  
 
We have selected patients with established disease in the two years prior to anti-
TNF therapy and therefore likely to have progressive disease in order to study and 
compare the sensitivity to change of each method. The exact chronology of 
radiographic change in psoriatic arthritis is not yet established and therefore it is 
possible the scores may perform differently in early disease. A final potential 
limitation is that we have scored the radiographs with the assumption of no 
improvement as stipulated in the Sharp-van der Heijde scoring instructions.  We 
applied the same rule to all methods to avoid biasing the results.  Unblinded 
reporting may have had the effect of overestimating the standardised response 
mean of the Steinbroker which includes soft tissue swelling which may well 
improve over the study period.  
 
I have found that the modified Sharp and Sharp-van der Heijde methods are the 
most reliable and sensitive to change in this present study, but took longer to 
perform.  The Steinbroker is the most feasible but lacks the sensitivity of the 
modified Sharp and Sharp-van der Heijde methods. The smallest detectable 
change of the psoriatic arthritis Ratingen is close to that of the modified Sharp and 
Sharp-van der Heijde methods but is quicker to perform and may be more specific 
to PsA through inclusion of proliferation.  The findings of this study can be used 
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to inform discussion on potential modifications and further study of these existing 
radiographic scoring methods for use in PsA longitudinal observational studies.  
 
For the purposes of my thesis I have chosen the psoriatic arthritis Ratingen score 
as the measure of radiographic damage for two reasons.  It is the only score that 
includes PsA specific radiographic change though the inclusion of bone 
proliferation.  Furthermore the psoriatic arthritis Ratingen offers an appropriate 
balance of feasibility (over the modified Sharp and Sharp-van der Heijde 
methods) and sensitivity to change (over the Steinbroker) for the study undertaken 
in chapter eight.  
 
The body of work of this thesis thus far has related to a review of the literature 
(chapter I) and then the development or assessment of classification criteria 
(chapter II) and outcome measures (chapters III and IV).  The final results chapter 
of this thesis applies these measures and criteria to a cross sectional study of WD 
in PsA to address explore the associations of WD with structural damage 
(objective 4b), disease activity, clinical patient reported outcome measures, 




CHAPTER VII  
 
DISEASE AND SOCIOECONOMIC ASSOCIATIONS OF 
WORK DISABILITY IN PSORIATIC ARTHRITIS 
 
This current chapter explores the associations of work disability with structural 
damage (objective 4b), disease activity, clinical PRO’s, demographic and 
socioeconomic factors (objective five).  In order to achieve these objectives and to 
allow future longitudinal study of WD as part of planned postdoctoral studies a 
multicentre observational cohort study design has been employed in a study 
named Long Term Outcomes in Psoriatic Arthritis II (LOPAS II).  This chapter, 
and hence the objectives 4b and 5 will be addressed through analysis of the cross 
sectional baseline data from LOPAS II. I conceived the LOPAS II study protocol, 
led the funding, ethical approval, running and reporting of the study.  The body of 




The existing body of knowledge relating to WD in PsA has been reviewed in 
chapter II.41  In summary there is intermediate quality evidence that levels of 
unemployment (20-50%) and WD (16-39%) are high and associated with longer 
disease duration, worse physical function, high joint count, low educational level, 
female sex, erosive disease and manual work.  There is sparse low quality 
evidence that WD is worse in those with PsA than psoriasis alone. Interpretation 
of this data is hampered by the small number of reports and heterogeneity of data 
collected.  In particular data on the associations of WD are limited by the prior 
lack of a validated measure.  I set out to determine to what extent structural 
damage, clinical disease activity, demographic and social factors are associated 
with unemployment, absenteeism, presenteeism and productivity loss measured 
with the work productivity and activity index. 
 
METHODS 
LOPAS II is a multicentre observational cohort study of four hundred patients 
with PsA conceived to explore the associations of WD with disease activity and 
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study the effect of drug treatment.  Hospitals at twenty three sites across England 
participated in this study (figure 1), recruited through support from the National 
Institute of Health Research (NIHR). Patients fulfilling CASPAR criteria for PsA 
commencing a new DMARD or anti-TNF treatment were recruited to this two 
year follow up study.  Follow up was based on routine clinical care such that 
follow up was twelve weekly if the treating clinician considered the psoriatic 
arthritis to be poorly controlled and six monthly if well controlled.  LOPAS II is 
an observational study with no treatment protocol, individual treatment decisions 
were made by the treating clinician.  The following outcome data was collected at 
the routine clinic visits: physician assessment (DAPSA composite score) and 
patient reported outcomes (physical function- health assessment questionnaire, 
health related quality of life- EQ5D, fatigue- FACIT, skin specific quality of life- 
DLQI, global and domain specific disease activity visual analogue scores, 
comorbidities, demographic details, education, location, employer 
awareness/helpfulness Likert scale) and international standard classification of 
occupations- ISCO work type.  Radiographs of the hands and feet were taken at 
the baseline visit and scored with the psoriatic arthritis Ratingen score.  Work 
disability was assessed with the WPAI which reports work disability as 
percentage of; absenteeism (work time missed), presenteeism (impairment at 
work/ reduced effectiveness) and work productivity loss (overall work 
impairment/ absenteeism plus presenteeism).  Details regarding the individual 
outcomes are found in the methods chapter.  The patient information sheet and 
consent form can be found in appendix 9 and 10 respectively.  
 
Statistical analysis 
Statistical analysis of demographic data has been undertaken in SPSS v20 by the 
author (WT).  Associations between potential explanatory variables and 
unemployment status were examined using multivariate logistic regression and 
with per cent presenteeism and productivity loss amongst those of working age 
using multivariate linear regression models.  The distribution of absenteeism 
showed small numbers in a number of categories and was converted into a binary 
variable representing either present (0%) or absent (100%) and analysed using 
multivariate logistic regression.  The regression analyses were undertaken using 
the statistical package R (2011) by GS.  All measured variables were considered 
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for inclusion, including location.  Age demonstrated a non-linear relationship 
therefore a quadratic term was applied.  Two way interactions were considered in 
all models but no significant effects at this level were observed. 
 
RESULTS 




Figure 1 Location of study sites for the LOPAS II study. Sites are labelled by 
number recruited at each site 
 
Of the 400 participants three hundred and eighteen were of UK working age (18-
65 years), mean age 46.8 years (sd 11.02), mean disease duration 5.8 years (sd 
8.00), 49.9% female.  Two hundred and twenty six of the study participants (64%) 
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were in work with a further ten over retirement age, but still working.  Ninety two 
participants of working age (26%) were unemployed.  Comparison of 
demographic, clinical, radiographic and socioeconomic factors of those working 
(any age) and those not working (18 -65 years only) are presented in table 1.  
 
Absenteeism, presenteeism and productivity loss of the 236 participants in work 
the mean was 14% (sd 29.0), 39% (sd 27.2) and 46% (sd 30.4) respectively 




Figure 2 LOPAS II participant patient reported work disability amongst 
employed participants over the preceding seven days measured with the WPAI 
estimated  
 
Negative influences upon remaining in employment included greater age, duration 
of two to five years and worse physical function (Table 2).  The effect of age was 
an odds ratio (OR) of 0.99 (95% CI 0.994 to 0.999, p=0.02) such that for every 




Table 1 LOPAS II comparison of study participants working (any age) and those 
unemployed (working age) 
Variable Not Working 
(working age) N= 92 
Working 




Age mean(sd) 55 (14.7) 48 (11.01) <0.001 
Sex male (%) 44% 50.1% 0.318 
DISEASE FACTORS 
 
Arthritis duration years mean (sd) 8 (9.8) 5.8 (7.77) 0.045 
DAPSA mean (sd) 45 (26.1) 45 (29.7) 0.930 
68 Tender joint count mean (sd) 17 (14.8) 15 (11.6) 0.284 
66 Swollen joint count mean (sd) 8 (6.9) 7 (6.8) 0.578 
CRP mean (sd) 14 (18.2) 15 (29.8) 0.676 
Global VAS 0-100 mean (sd) 62 (23.8) 66 (65.8) 0.960 
Pain VAS 0-100 mean (sd) 61 (24.9) 65 (66.1) 0.566 
Joint VAS 0-100 mean (sd) 62 (22.9) 68 (91.5 0.780 
Skin VAS 0-100 mean (sd) 39 (30.3) 46 (93.1) 0.769 
HAQ 0-3 mean (sd) 1.3 (0.78) 1 (0.68) <0.001 
EQ5D VAS 0-100 mean (sd) 0.4 (0.36) 0.5 (0.28) 0.013 
FACIT mean (sd) 22 (10.9) 21 (9.9) 0.247 
DLQI 0-30 mean (sd) 5 (5.9) 4 (5.3) 0.297 
Radiographic score: 
RATINGEN 0-360 mean (sd) 
19 (31.7) 8 (16.4) <0.001 






 Productivity loss 







ISCO work type valid % (n) 
 Managers 
 Professionals 
 Associate professionals 
 Clerical 
 Sales 
 Skilled agricultural 
 Craft 






























 Very helpful 
 Helpful 
 No help required 
 Unhelpful 


















 No formal education 
 Lower secondary 
















*Comorbidities yes if any of Diabetes, Hypertension, Hypercholesterolemia, Cerebrovascular disease or Cardiovascular disease, % displayed is the valid per cent. 
Difference between working/ not working ANOVA P value. 
DAPSA- disease activity in psoriatic arthritis, CRP, C reactive protein, VAS visual analogue scale, HAQ health assessment questionnaire, EQ5D Euoroqol 5 
domains score, FACIT functional assessment of chronic illness therapy, DLQI dermatology quality of life index, WPAI work productivity and activity questionnaire 
ISCO International classification of occupation
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likely to achieve clinical significance when considered over decades.  Disease 
duration of 2 to 5 years exerted a strongly negative influence upon remaining in 
employment OR 0.41 (95% CI 0.180-0.953 p=0.03).  The association of worse 
physical function with unemployment was also strong, such that the risk of 
unemployment increased by OR 0.56 (0.343 – 0.926, p=0.02) for every increase 
of 1 in the health assessment questionnaire (HAQ score range 0-3).  Finally 
employer helpfulness exerts a strongly positive influence on remaining in 
employment.  If participants rated an employer as helpful the likelihood of 
employment was increased by an OR of 15.10 (95% CI 4.658-69.355, p=<0.01).  
This positive effect was sustained even if the participant perceived that no help is 
required, OR 3.22 (95% CI 1.264-8.229, p<0.01).  
 
Table 2 Associations with employment/ unemployment (working age) 
Variable Model 1- logistic 
Employed 
Odds Ratio (CI)  
236 patients 
Intercept 0.01 (0.000 to 1.622) p=0.07  
Age years  1.31 (1.029 to 1.672) p=0.03 
Age (quadratic) years 0.99 (0.994 to 0.999) p=0.02 
Disease duration 2-5 years (n=61) 0.41 (0.180 to 0.953) p=0.03 
Disease duration >5 years (n=80) 1.36 (0.557 to 3.319) p=0.49 
HAQ 0-3 0.56 (0.343 to 0.926) p=0.02 
Employer very helpful (n=63) 15.10 (4.658 to 48.753) p<0.01 
Employer helpful (n=43) 17.46 (4.395 to 69.355) p<0.01 
No help required (n=59) 3.22 (1.264 to 8.229) p<0.01 
Employer unhelpful (n=18) 1.29 (0.325 to 5.155) p=0.72 
Employer very unhelpful (n=9) 0.39 (0.039 to 3.942) p=0.42 
Intercept: represents the odds ratio when all variables are zero such that age is zero, 
disease duration 0-1 years, global/ joint VAS zero, HAQ zero, Employer unaware, 
Significant associations in bold. 
 
 
Absenteeism as a binary variable (present or absent over the prior week) was 
associated with worse joint activity visual activity scale (0-100) such that for 
every increase in of 10 the OR of absenteeism increased by 4% (OR 1.04 (95% CI 




Greater global, joint specific disease activity and worse physical function exerted 
a negative influence on presenteeism and productivity loss (Table 3).  For every 
increase in global disease activity visual analogue scale (0-100) of 10 there was an 
increase of presenteeism of 2% (estimate 0.02, 95% CI 0.001-0.053, p=0.01) and 
3% for productivity loss (estimate 0.03, 95% CO 0.003-0.55, p=0.01).  Worse 
physical function was strongly associated with more presenteeism and 
productivity loss.  For every increase in health assessment questionnaire of 1 
presenteeism was 47% higher (estimate 0.63, 95% CI 0.005-1.200, p=0.03) and 
productivity loss 12% higher (estimate 0.12, 95% CO 0.066-0.182, p<0.01). 
 
Table 3 Associations with presenteeism and productivity loss amongst those 
working (any age) n=200 
Variable Model 2- Linear 
Presenteeism (0-1) 
Estimate (CI)  
 
Model 3- Linear  
Productivity loss (0-1) 
Estimate (CI)  
 
Intercept -0.02 (-0.114 to 0.074) p=0.67 -0.05 (-0.143 to 0.040) p=0.27 
Disease duration 2-5 years (n=36) 0.02 (-0.066 to 0.112) p=0.61  
Disease duration >5 years (n= 63) -0.09 (-0.167 to -0.021) p=0.01  
Global activity VAS 0-10  0.02 (0.001 to 0.053) p=0.01 0.03 (0.001 to 0.06) p<0.01 
Joint activity VAS 0-10 0.03 (0.006 to 0.055) p=0.01 0.02 (0.000 to 0.049) p=0.05 
HAQ 0-3 0.63 (0.005 to 1.200) p=0.03 0.12 (0.066 to 0.182) p<0.01 
Intercept: represents the estimate when all variables are zero such that age is zero, disease duration 0-1 years, 
global/ joint VAS zero, HAQ zero, Employer unaware, Significant associations in bold 
 
DISCUSSION 
I report the associations of unemployment, absenteeism, presenteeism and 
productivity loss amongst a well classified cohort of patients with PsA. 
 
With regards to unemployment we report the novel findings that greater age and 
recent disease are associated with unemployment.  Furthermore patient reported 
employer awareness and helpfulness exerts a strongly positive influence on 




The British society of rheumatologists biologics register is the only study to date 
to investigate the influence of age upon employment and did not find an 
association.39  The study by Wallenius et al examined disability benefit collection 
in a cohort of patient with PsA aged between 18-45 years controlled for age in 
their regression.9  In this present study the absolute effect of each year of age upon 
becoming unemployed is small, an increase of 1% for every additional year of 
age.  PsA is however a chronic disease and when considered over decades this 
effect would become a clinically meaningful burden.  
 
Four studies have previously reported that increasing disease duration negatively 
influences remaining in employment.9, 39, 54, 73  The finding in our present study of 
increased unemployment in those with early disease (2 to 5 years) is an interesting 
one and in keeping with the finding of high levels of unemployment in the first 
five years of rheumatoid arthritis reviewed by Nikiphorou et al137,.  Reports in 
rheumatoid arthritis have been inconsistent as reviewed by de Croon et al.43  The 
findings in this present study of increased unemployment in those with disease for 
2-5 years do differ from prior reports in PsA and differences in study designs may 
account for this.  First, two studies were restricted to patients on anti-TNF 
introducing the possibility of confounding by indication.39, 73  Second, differing 
social security systems may influence an individual’s decision to stop work and 
the other three studies were conducted in countries other than the UK; Germany54 
Norway9 and Sweden73.  Finally I have measured relatively short duration 
absenteeism with the WPAI which has a recall period of one week whereas these 
prior studies were based on government social security benefit collection records 
thus measuring more long-term absence from work.  
 
To my knowledge this is the first time patient reported employer helpfulness has 
been investigated in PsA. The findings of this study suggest that patient reported 
employer awareness and helpfulness are positively associated with remaining in 
employment, even if patients perceive no help is required. The strength of the 
association between employer helpfulness and employment in the regression 
model may account for variables identified in previous studies such as worse 
physical function9, 39, 70, joint disease39, 70, 71, fatigue70, erosive disease9, sex9, 39, 73 
and education9, 54 not achieving significant associations and inclusion into the 
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final models.  This finding emphasises the multifactorial influences upon WD and 
the importance of accounting for as many potentially confounding factors as 
possible.  
 
Relating to absenteeism, presenteeism and productivity loss amongst those at 
work we report that only disease activity factors rather than demographic or 
socioeconomic factors influence performance.  Specifically in this present study 
greater global, joint specific disease activity and worse physical function exerted a 
negative influence on presenteeism and productivity loss.  Furthermore disease 
activity measures appear to exert a greater influence than severity (radiographic 
damage), which did not achieve inclusion into the final models.  This is an 
interesting finding suggesting that although there are multiple potential 
influencing factors targeting disease may be appropriate when considering 
approaches to reducing absenteeism, presenteeism and productivity loss.  
 
Prior studies have reported reduced patient reported work productivity amongst 
those taking anti-TNF for PsA39, 70, 71 however we report this finding amongst a 
wider population of patients taking both DMARD and anti-TNF treatment.  The 
magnitudes of the associations of presenteeism with global and joint specific 
disease activity are modest (2% and 3% per 10% increase respectively).  There is 
no data on the minimally important difference of presenteeism in PsA and this is a 
subject of further research by our group.  
 
The finding that global and joint specific activity but not the domain of skin 
disease (skin specific activity visual analogue score or DLQI) reached statistical 
significance in the final models is consistent with prior reports comparing patients 
with PsA and those with psoriasis alone.  Two studies have reported increased 
WD amongst patients with PsA versus patients with psoriasis alone.48, 51  To my 
knowledge this is the first study reporting the relative impact of joint and skin 
disease on WD and indicates that joint disease exerts the greatest influence in this 
cohort.  It should be noted that the level of skin activity compared to joint activity 
was low (39% skin visual analogue versus 62% joint visual analogue amongst 
those not working).  It is known that domains of disease activity can be divergent 
in PsA and the selection of patients in this study was from rheumatology clinics in 
92 
 
those having treatment escalation for PsA.  By including people with relatively 
mild skin disease I may have overestimated the relative influence of the joint 
domain.  Nonetheless the finding in this study that disease activity measures, 
which are potentially reversible, exert a negative influence upon performance at 
work adds strength to the theory that presenteeism/ productivity loss can be 
improved with treatment.  
 
This study has a number of strengths and scores six out of seven (high quality) 
when measured against the quality measure from the systematic review in chapter 
three.  The first strength is that the cohort is well classified; all participants fulfil 
the CASPAR criteria for PsA.  Second work disability is the primary endpoint for 
LOPAS II and thus has data on multiple potential confounding factors available 
for inclusion in the analysis and we have measured a variety of types of WD 
(unemployment, absenteeism, presenteeism and productivity loss).  Participants 
have been recruited regardless of age and this has enabled the dual analysis of 
unemployment amongst those of working age and measures of reduced 
effectiveness (WPAI) amongst those in work regardless of age.  Third this is the 
first study to measure WD in PsA with a tool that has preliminary evidence for its 
validity PsA.115  Finally the multicentre nature of the study increases the 
generalizability of the findings.  
 
The findings of this study need to be interpreted in light of certain methodological 
limitations.  The multicentre study design allows a better reflection of 
socioeconomic status of the UK population and recruitment over an achievable 
timeframe.  However there are a number of design limitations this introduces.  
First, the twenty-three recruiting centres were located across England though did 
not include London, potentially limiting the generalisability of the results. I have 
employed a spatial model to assess for geographic variation in WPAI however 
and no differences were detected. Second, the study design needed to be 
minimally burdensome to patients and clinicians to be taken on at multiple 
National Health Service (NHS) sites across the UK.  This means that the data 
collection forms needed to be short enough to be feasible in this setting.  As a 
result some data that may have been useful has not been collected to optimise 
feasibility such as a clinicians assessment of the psoriasis with a psoriasis area and 
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severity score (PASI).  The PASI score was deemed too time consuming to 
conduct in clinical practice and the collection of the visual analogue score for skin 
and DLQI have both been collected and are known to correlate well with the PASI 
score.72, 97  Third, involving multiple sites increases the number of assessors 
thereby increasing measurement error for the clinically assessed tender and 
swollen joint count.  I have made every effort to minimise inter rater variance 
across sites by providing one-to-one joint count training at the lead site (Royal 
National Hospital for Rheumatic Diseases- RNHRD), providing standardised joint 
count training material (DVD, poster and booklet) and encouraging the same 
assessor to perform all assessments at teach site.138  Fourth, the inclusion criteria 
and sample size calculation were based on the prospective study to determine the 
difference between change in presenteeism between DMARD and anti-TNF 
treatment therefore the study that, after discussion at the transfer viva and with 
NJM and CdeV will now be undertaken as postdoctoral studies.  Fifth, the study 
participants were recruited to the LOPAS II study at the time a new drug was 
commenced and therefore represent a group with active disease.  Through 
selection of a cohort with active disease the influence of disease activity on WD 
may be over emphasised.  Sixth, with respect to the assessment of employer 
helpfulness it should be noted that the Likert scale used in this study has not been 
validated. Further work to validate this measure is planned as part of post-doctoral 
studies. Finally there are some potential confounding factors that have not been 
included in this study such as depression, financial status and desire to work. 
Nonetheless the findings of this present study are certainly applicable to patients 
with active PsA and add to the evidence that active disease adversely affects WD.   
 
In conclusion greater age, recent disease onset (2 to 5 years disease duration) and 
worse physical function exert a negative influence on remaining in employment.  
Patient reported employer awareness and helpfulness exerts a strongly positive 
influence on remaining in employment, even if patients perceive no help is 
required.  In contrast in those who remain at work reduced effectiveness 
(presenteeism and productivity loss) are associated with the disease activity 
measures of greater global, joint specific visual analogue scales and worse 
physical function.  Further prospective study is underway to investigate whether 
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ameliorating disease activity improves absenteeism, presenteeism and 







The aims of my thesis were to systematically and critically review the current 
body of knowledge of work disability in psoriatic arthritis, examine the validity of 
the WPAI, estimate the burden of work disability using this tool and investigate 
the associations with disease activity, structural damage, demographic and social 
factors.  My thesis reports a new body of knowledge addressing these objectives.  
The weaknesses of the individual studies have been discussed in the individual 
chapters and are not specifically revisited here.  In this chapter I will discuss the 
findings of my thesis, by order of each objective, highlighting the key findings 




Objective one of my thesis was to systematically review the current body of 
knowledge of work disability in PsA.  I report the first systematic review of work 
disability in psoriatic arthritis, with the following key findings:41 
 There is intermediate quality evidence that work disability in PsA is high 
and is associated with longer disease duration, high health assessment 
questionnaire, high joint count, low educational level, female sex, erosive 
disease and manual work.  
 There is sparse low quality evidence that work disability may be worse in 
those with PsA than psoriasis alone.  
 There is no data on work disability in early PsA, the relative contribution 
of psoriasis in those with PsA or the role of other co morbidities such as 
fatigue, depression or the metabolic syndrome.  
 Finally the evidence that disability at work is mitigated by treatment is 
limited to a small number of short duration biologics RCTs. 
 
There has been increasing focus on work as an outcome in rheumatic disease 
during the conduct of this thesis.  The journal ‘Rheumatology’ dedicated a themed 
edition to ‘work in rheumatic disease’ in 2012 (Issue 51) highlighting this 
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interest.116  More recently a study reported in abstract form by Gossec et al has 
drawn attention to the importance of work from the individual patient’s 
perspective.  This study, presented at the EULAR conference in 2013 reported the 
preliminary development of a new ‘impact of disease’ score- the Psoriatic 
Arthritis Impact of Disease score (PsAID).  This project incorporated the patient 
perspective from its inception with the intention of better capturing the true 
impact of disease. The first step in the PSAID study was to identify and select 
domains of disease to be included in the score.  Focus group sessions were used to 
identify domains.  One hundred and thirty nine participants were then asked to 
rank the identified domains according to the impact on their lives (physically, 
mentally and socially).  A novel and interesting finding here was that work was 
found to be a high priority, ranking fourth highest behind pain, skin disease and 
fatigue.139  The importance attributed to work disability by patients with PsA will 
be recognised by incorporation of work in the PsAID.   
 
The findings of the systematic review conducted in chapter two highlight the 
extent of the gaps in our current understanding of WD in PsA and identifies areas 
for further study including; the lack of a validated outcome measure, the lack of 
information in early disease and the incomplete understanding of the influencing 
factors.  The review may also be used as a source of evidence to quantify the 
impact of disease in PsA.  Quantifying the burden of disease is an important 
consideration when justifying the need for costly research and the systematic 
review will be a useful source of evidence. 
 
The findings of the systematic review have informed the conducted of the 
research in my thesis beyond identifying the current body of knowledge.  The 
review identified the lack of consensus on a measure of WD. Therefore I selected 
a work outcome that would allow separate analysis of individual work outcomes 
from presenteeism, absenteeism, productivity loss through to unemployment.  
This has enabled examination of influencing factors of each type of work 
disability.  During the conduct of the systematic review it became clear that many 
studies had restricted the age of participants, making interpretation of the findings 
complex, as entire demographic bands were not included (such as those over 
retirement age who are still in work).  Viewing this as a limitation to prior studies 
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I have not restricted the age of participants in the study examining associations 
with work disability (chapter seven).  Having no age restriction allows individual 
analyses amongst those of working age when examining absolute levels of 
employment and analysis of those in work, irrespective of age, when assessing 
absenteeism and presenteeism. 
 
Summarising the body of knowledge relating to work disability in psoriatic 
arthritis was hampered by a number of factors.  First, there have been multiple 
outcome measures used in the research to date.  These include, but are not limited 
to: unemployment, government records of disability benefit collection, 
absenteeism from work over varying lengths of time and patient productivity loss 
calculated in different ways (chapter 2, Tables 1 and 3).  Multiple outcomes may 
be expected in any emerging field, until consensus is achieved, and this is 
certainly the case in work disability.  In addition to a lack of consensus it has 
become clear that there is poor agreement between the existing candidate 
measures.68  This poor agreement leads to further uncertainty when comparing 
results between studies.  Second, the differing populations and study designs 
amongst the small number of studies make meaningful comparison of the results 
difficult.  Of particular note the studies to date are from a range of different 
countries, each with differing social security systems and therefore different 
incentives for leaving or remaining in the work place.  
 
In summary the study of work disability in psoriatic arthritis is an emerging field 
with evidence from a small number of diverse studies that there is a high burden 
of disability, no consensus on a measurement tool and a wide variety of disease 
and non-disease related influencing factors.  Evidence from the review has 
informed the conduct of the studies undertaken in my thesis and may be used in a 
wider setting to inform future research as well as contributing to the body of 
evidence relating to the burden and impact of PsA. 
 
OBJECTIVE TWO 
In order to examine the validity of the WPAI it was necessary to classify an 
existing cohort of patients to study.  Objective two was therefore to classify an 
existing cohort of patients with PsA, according to the CASPAR criteria.  The 
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cohort of patients’ at the Royal National Hospital for Rheumatic Diseases was 
started in 1989, however consensus on the use of the CASPAR classification 
criteria was only reached relatively recently in 2006.  Prospective re-classification 
of this cohort was deemed unfeasible so it was necessary to assess the 
performance of the CASPAR criteria when applied retrospectively from medical 
case notes.  I report the novel finding that:  
 The feasibility, specificity and sensitivity of the CASPAR criteria are 
maintained when adapted for retrospective use to classify an established 
research cohort from medical records even in those with missing data. 77 
 
This study has allowed the appropriate classification of an existing cohort of 
patients to study in order to address objective three.  The wider application of this 
study is limited, as there are relatively few pre-existing cohorts in the wider 
research community that need to be retrospectively classified.  Nonetheless it is 
important that any such cohorts are appropriately classified, as evidenced by the 
identification of fifteen patients amongst the RNHRD cohort whose diagnosis had 
changed from PsA since their original inclusion.  Decision making in 
rheumatology practice is dynamic as clinical diagnosis can and does change over 
time, sometimes very gradually over years.  As researchers we need to remain 
vigilant to such changes in long term observational cohorts and have appropriate, 
feasible and validated classification tools.  Therefore the evidence presented in 
this study may be used to classify existing cohorts with confidence, thereby 
allowing confident interpretation of study findings.76 
 
OBJECTIVE THREE 
Objective three of this thesis was to examine the feasibility, construct and 
discriminative validity of the WPAI in PsA.  I report the following novel findings 
supporting the validity of the WPAI in psoriatic arthritis:121 
 Evidence supporting the feasibility of the WPAI in psoriatic arthritis 
though ease of application, low cost and ready interpretation. 
 Evidence for the construct validity of the WPAI through correlation with 
other domains of disease activity including patient reported global disease 
activity, pain, physical function, health related quality of life and fatigue.  
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 Evidence for the discriminative validity of the WPAI through 
discrimination between better or worse disease defined by the medians of: 
patient reported global disease activity, pain physical function, health 
related quality of life and fatigue. 
 
This study therefore provides evidence supporting the validity of the WPAI in 
psoriatic arthritis.  When considering the remaining aspects of validity according 
to the OMERACT filter the domain of responsiveness of the WPAI in PsA is yet 
to be determined.  Responsiveness incorporates both sensitivity to change and 
stability of a measure when there has been no clinical change.  Validation studies 
of the WPAI in rheumatoid arthritis and ankylosing spondylitis have demonstrated 
the tool has good responsiveness.67, 79  A prospective study is required to assess 
this domain and there are plans to address this as part of post-doctoral studies. 
 
There are many work outcome measures available, as reviewed by Beaton et al, 
and the rationale for my selecting the WPAI has been discussed in the methods 
section.66  Briefly the WPAI is one of a small number of measures selected for 
further assessment by the OMERACT work special interest group and there is 
good evidence for its validity in two closely related conditions, rheumatoid 
arthritis and ankylosing spondylitis.67, 79  Despite these reports and the evidence 
reported in this thesis supporting the validity of the WPAI, doubt remains over the 
levels of agreement between the existing measures.  A recent study has 
demonstrated poor agreement in the estimates of productivity loss between four 
existing methods.68  In this study of 250 patients with OA and rheumatoid arthritis 
the average numbers of lost hours (SD) over the prior two weeks due to 
presenteeism measured by the HLQ, WLQ, HPQ, and WPAI were 1.6 (3.9), 4.0 
(3.9), 13.5 (12.5), and 14.2 (16.7) respectively.68  The cause of this poor 
agreement has yet to be determined.  It is possible these differences arise from 
underling differences in the psychometric properties of the questionnaires. Each 
questionnaire has been developed independently and the differences in the 
questions and calculation methods may underpin the variance.  However certain 
methodological considerations may in part account for these findings.  The 
questionnaires have differing recall periods (HPQ and WPAI one week,  HLQ and 
WLQ was two weeks) and arthritis is a variable condition with symptoms of 
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relapse and remission that may occur over very short periods of time, thus 
introducing variance to this study.  The questionnaires were applied in the same 
order to all participants, possibly resulting in a high missing rate for the HLQ 
which was the last questionnaire.  The results of any study examining work 
disability with these instruments should to be interpreted with caution until the 
underlying causes of these discrepancies are clarified.  
 
The assessment of work disability is in its relative infancy and although I have 
undertaken a study examining the validity of the WPAI in psoriatic arthritis 
questions (posed by members of the OMERACT work group) remains relating to 
the measurement of work disability. These questions include:66, 119  
 How best to combine information on absenteeism and presenteeism? 
 Should general work impairment or activity specific be measured?  
 How to incorporate job transition or adaptation in a measure of disability? 
 What should the length of recall be; weeks, months or years?  
 Should work disability be attributed to disease or should it remain 
unrestricted? 
 Should only paid work be assessed or should unpaid work be included? 
 Exactly what aspect of work disability should be measured?  
Historically aspects such as absenteeism, presenteeism, productivity loss, 
impairment, job instability (perceived risk of work cessation) and impaired 
performance have all been measured.  There was increasing consensus at the 
OMERACT 10 meeting that a measure combining absenteeism and presenteeism 
should be taken forward for further development and six measures including the 
WPAI were selected as having potential.140  Therefore when considering the 
findings of this study in the wider context it may be considered that I have added 
information on the validity of one measure in PsA but ultimately an alternative or 
entirely new measure of WD may be taken forward by the wider research 
community, limiting the future use of these findings.  
 
In summary I report new evidence supporting the feasibility, construct validity 
and discriminative validity of the WPAI in psoriatic arthritis. These findings 
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support the use of the WPAI in patients with PsA but do not constitute a full 
validation as the domain of responsiveness is yet to be determined.  
 
OBJECTVE FOUR (a) 
Objective four (a) of this thesis was to assess the feasibility, reliability and 
sensitivity to change in structural joint damage of the four existing radiographic 
assessment methods in psoriatic arthritis.  The use of plain radiographs to assess 
structural damage is routine in clinical practice and an important measure of 
structural damage in longitudinal observational studies.  Plain radiographs are 
inexpensive, quick to perform, acceptable and readily interpretable.  There was 
agreement amongst experts at the radiographic assessment workshop at the annual 
GRAPPA meeting in Stockholm 2012 that the Sharp-van der Heijde modified 
method was the optimal method for use in short duration randomised controlled 
trials however there was no agreement on the optimal method for longitudinal 
observational studies.  I report the first comparison of four radiographic scoring 
methods in psoriatic arthritis with the novel findings that:121  
 The modified Sharp score and van der Heijde methods are the most 
reliable and sensitive to change but take longer to perform.  
 The Steinbrocker method is the most feasible but lacks the sensitivity of 
the modified Sharp score and van der Heijde method. 
 The smallest detectable change of the Ratingen method is close to that of 
the modified Sharp score and van der Heijde method but is quicker to 
perform and may be more specific to PsA through inclusion of bony 
proliferation. 
 
The selection of any outcome measure, including a radiographic one, is always 
likely to remain a study specific decision.  In particular individual studies will 
have differing requirements for truth, reliability and feasibility.  For example 
outcome in a genetic association study may rank specificity to disease highest 
when choosing a method and as such the Ratingen may be the most appropriate as 
it includes bony proliferation, the only radiographic feature sufficiently specific to 
PsA to achieve inclusion in the CASPAR criteria.  Alternatively a short duration 
phase III drug trail may prioritise sensitivity to change and thus the van der Heijde 
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may be most appropriate.  The findings of this study have enabled a data driven 
selection of the Ratingen method on the basis of feasibility, specificity and 
sensitivity to change.  
 
When considering the findings of this study in the wider context of psoriatic 
arthritis research this data may inform the selection of radiographic methods in 
other observational studies of PsA. This is the first study to report the minimal 
detectable change of the Steinbrocker and Modified Sharp Scores in PsA and this 
data can be used to inform sample size calculations for future studies.  The data 
can also inform discussion on radiographic outcome in observational studies with 
a view to more consistency in the use of a single measure.  Consistency in the use 
of the same method introduces the possibility of increasing the collaboration of 
data between cohorts, comparison between studies and possibly meta-analyses.  If 
no consensus can be achieved the data from this study may allow the development 
of a novel radiographic score in psoriatic arthritis, potentially derived through 
mathematic reduction to achieve maximum sensitivity to change from the 
minimum areas scored.  Such a score would then need to be assessed on a larger 
scale, including on patients with early psoriatic arthritis.  
 
In summary I report new data comparing the feasibility, reliability and sensitivity 
to change of four radiographic scoring methods in psoriatic arthritis.  This 
evidence has allowed a data driven selection of the most suitable measure for use 
in my study but the results may be used by the wider PsA research community to 
make a data driven selection of study specific measures, calculate sample size or 
potentially develop a novel measure.  
 
OBJECTIVE FOUR (b) & FIVE 
Objectives four (b) and five of this thesis were to determine the extent to which 
radiographic damage, clinical disease activity, demographic and social factors are 
associated with WD measured with the WPAI.  In this multicentre, cross sectional 
observational study I report the novel findings that amongst those with PsA of 
working age: 
 Greater age, recent disease onset (2 to 5 years disease duration) and worse 
physical function exert a negative influence on remaining in employment. 
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 Patient reported employer awareness and helpfulness exerts a strongly 
positive influence on remaining in employment, even if patients perceive 
no help is required.  
These findings are in contrast with those of any age who remain at work where 
presenteeism and productivity loss are associated with the disease activity 
measures of: 
 Greater global activity, joint specific activity and worse physical function.  
 
Gaining further understanding of the breadth of the work disability concept and 
highly contextual nature of WD were seen as key issues at OMERACT 10.117  The 
importance of separately measuring individual WD perspectives was specifically 
highlighted.  This study has been designed to separately analyse the individual 
perspectives of productivity loss, presenteeism, absenteeism and unemployment.  
A broad range of contextual factors were included in addressing objective five of 
this thesis.  An interesting finding of this study has been the identification of the 
association of patient reported employer helpfulness (chapter seven, table two) 
with remaining in employment.  Employer attitude has been discussed as 
conceptually important by Sandqvist  and Henriksson141 and voted as important to 
investigate at the OMERACT 10 work SIG117, but to my knowledge this is the 
first report of the positive influence of employer attitude upon remaining in 
employment.  This association was not seen with presenteeism, absenteeism or 
productivity loss.  Investigation of this finding in a prospective study would allow 
confirmation of any temporal relationship between patient reported employer 
attitude and unemployment.  
 
It should be noted that there are contextual factors that were not included in this 
present study including; co-worker attitude (in addition to employer attitude), 
depression, job satisfaction/ motivation, individual income need and demands and 
support at home.  The latter was the top rated contextual factor at the OMERACT 
10 work SIG, receiving 26% of votes.117  These potentially important confounding 
factors may also influence the reported findings.  The strength of the association 
of employer helpfulness rarely assessed in work studies, that replaced other more 
frequently reported associations (such as sex, education, work type and 
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radiographic damage) in the regression model. This highlights the effect that 
missing confounding factors may have upon study findings and thus the 
importance of confirmation in prospective studies.  
 
The association of radiographic damage with presenteeism, absenteeism and 
productivity loss was not sufficiently strong to warrant inclusion in the final 
regression models.  The associations of disease activity measures with WD 
‘pushed’ demographic, social factors as well as out radiographic damage of the 
model (chapter seven, table three).  This finding supports the notion that, despite 
the many influencing factors, presenteeism could be a responsive measure 
reflecting disease activity.  The association of radiographic damage with 
unemployment was also insufficiently strong to warrant inclusion in the final 
regression model replaced with age, disease duration, physical function and 
employer helpfulness (chapter seven, table two).  The findings of this study 
indicate that unemployment, the work disability ‘endpoint’, may be associated 
with demographic and social factors (employer helpfulness) rather than structural 
damage or disease activity.   
 
The influence of time upon work disability also warrants discussion as both work 
disability and psoriatic arthritis may fluctuate over time. As discussed in the 
introduction and the systematic review of this thesis there are multiple factors that 
may influence WD and their relative contribution may change over time.  For 
example a period of economic recession followed by recovery may directly 
impact upon employment.  Additionally the psoriatic arthritis may relapse and 
remit over days, weeks or months.  The WPAI measures disease only over a one 
week period and may therefore fail to capture change outside this timeframe and 
potentially interact with the findings of any study using the WPAI, or any other 
measure with a short recall period.  Conversely a recall period of one week may 
be regarded as a strength of the WPAI.  Over a longer period (such as a month in 
the case of the WLQ) the response would be an average of flares and remissions 
over that time.  The process of averaging will thereby potentially both 
underestimate the effect of disease activity (by including periods of remission) 
and miss fluctuations thus resulting in a less responsive measure.  The study 
comparing four WD measures in rheumatoid arthritis and osteoarthritis by Zhang 
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et al support this theory with the finding that measures of WD over longer recall 
periods estimate WD lower than those that measure over a shorter time such as the 
WPAI.68 Finally a measure with a short recall period of one week minimises the 
risk of recall bias and allows direct comparison with other disease outcome 
measures such as the HAQ, DLQI, VAS, EQ5D, FACIT which all have a recall 
period of one week.  I would therefore suggest that a measure of WD with a 
shorter recall period is desirable but does introduce the risk of interacting with 
study findings by missing WD outside the recall period.  
 
In summary I present new data on the associations of patient reported work 
disability in psoriatic arthritis from a well classified cohort of patient’s recruited 
from across the UK.  Presenteeism and productivity loss amongst those in work 
are associated with the disease activity measures.  This is in contrast to 
unemployment which is associated with age, disease duration, physical function 







The lack of evidence relating to work disability in early PsA identified in the 
systematic review and has not been addressed in this thesis.  Studies in 
rheumatoid arthritis suggest that work disability occurs early in disease and may 
be irreversible as reviewed by de Croon et al.43  There is therefore a case for 
assessing factors that influence work disability in early PsA with a view to 
developing a strategy for preventing or minimising the impact in early disease.  
This could be addressed with a mixed methods inception cohort study, qualitative 
interviews exploring influencing factors followed by quantitative assessment with 
medical and patient reported assessment over the first five years of disease.  
 
Another area of limited evidence identified in the systematic review is the effect 
of medical treatment upon work disability. There is evidence suggesting 
biological therapy with anti-TNF treatment can improve work disability but this 
evidence comes from short duration drug RCT’s and thus relates to a highly select 
group of patients with limited follow up.41  A prospective study of the ‘real world’ 
effect of disease modifying and anti-TNF treatment on WD is underway as part of 
planned post-doctoral studies (LOPAS II, appendix 9). 
 
The lack of consensus on the existing measures of work disability and the possible 
development of a new measure are the subject of on-going research.117 Once a 
consensus has been achieved this will enable more confident interpretation of the 
findings of individual research projects and comparison of cohorts.  
 
Once these three areas of measurement, influencing factors in early disease and 
the effect of treatment have been addresses the next step may be to consider an 
interventional case control study comparing multidisciplinary intervention. Such a 
study would compare a novel intervention aimed specifically at the improvement 
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